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Topical therapya b s t r a c t
Recent years have, surprisingly, witnessed an increase in incidence of sexually transmitted infections
(STIs). At the same time, antimicrobial therapy came under the threat of ever rising antimicrobial resis-
tance (AMR), resulting in STIs with extremely limited therapy options. In this review, we addressed the
challenges of treating vaginal infections in an era of AMR. We focused on published work regarding nano-
medicine destined for localized treatment of vaginal infections. Localized therapy offers numerous
advantages such as assuring high drug concentration at the infection site, limiting systemic drug expo-
sure that can lead to faster development of AMR reduction in the systemic side effects and potentially
safe therapy in pregnancy. We provided a state-of-the-art overview of nanoformulations proposed to
topically treat STIs, emphasizing the challenges and advantages of each type of nanocarriers, as well as
issues of potential toxicity.
 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license
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This century brought an increased focus on women’s health
with emphasis on developing new means for efficient delivery of
drugs locally within vaginal cavity. Many of the formulations and
devices aim to prevent a range of health conditions women expe-
rience as well as efficiently treat infections. Emerging multipur-
pose technologies have been proposed to offer broad-spectrum
prevention for sexually transmitted diseases and contraception
[1]. However, it was assumed that infectious diseases are mostly
treatable before emerging concerns related to antimicrobial resis-
tance (AMR) reported for many of most powerful antimicrobials
[2]. In the current review, we address the specific challenges of
treating vaginal infections in an era of ever-growing AMR.
Different antimicrobials in novel delivery systems including
nanosystems, have been proposed as formulations for localized
therapy of vaginal infections [3–9]. Before discussing the specific
situation of treating vaginal infections in an era of AMR, we sum-
marize the advantage of treating vaginal infections locally, rather
than systemically.
Topical treatment of vaginal infections could offer several
advantages:
i) achieving high concentration of antimicrobials within vagi-
nal cavity would lead to improved drug therapy at site of
infection;
ii) reducing systemic exposure to antimicrobials would reduce
the resistance development;
iii) reduced systemic exposure could lead to reduced side effects
thereof possible treatment of pregnant women (Fig. 1).
Vaginal infections can be treated by various formulations; con-
ventional, as well as advanced, that are not within nanorange such
as hydrogels, films, etc [6,10]. We focused on localized treatment of2
vulvovaginal infections by utilizing nanomedicine. We structured
the review to address first the alarming sexually transmitted infec-
tions (STIs) with most serious AMRs challenge, followed by most
spread infections. Where available, we commented on the alterna-
tives to conventional antimicrobials such as natural origin sub-
stances that might offer lesser potential for AMR.
Prior to discussing the current state-of-the art in antimicrobial
nanomedicine-based topical vaginal therapy, the current rather
alarming situation regarding STIs is summarized.2. Treating sexually transmitted infections (STIs) in era of AMR
2.1. Vaginal microbiome and infection
In women of reproductive age, vaginal microbiome is a dynamic
ecosystem affected by the estrogen levels, presence of lactobacilli
and low pH. An ideal formulation for intravaginal delivery should
not impair the vaginal environment and balance within normal
microbiota [11]. It is worth noting that vaginal microbiome is
much better defined than the vaginal mycobiome [12] although
Candida albicans was the most frequently isolated fungus, which
caused lower genital tract infections in about a third of women
aged 15–24.
Vaginal dysbiosis, term describing abnormal vaginal micro-
biome comprising bacterial vaginosis and desquamative inflamma-
tory vaginitis, has confirmed links to adverse pregnancy outcomes,
pelvic inflammatory disease, an increased risk of STIs, and other
reproductive health problems, such as a poor outcome of in vitro
fertilization [13]. The pathological vaginal discharges can also be
linked to the presence of lactobacillus overgrowth, known as cyto-
lytic vaginosis (CV). The CV is becoming increasingly prevalent;
moreover, it is frequently misdiagnosed. Treatment of CV requires
clinical approaches that differ from those applied to other types of
bacterial vaginosis (BV) [14,15]. The vaginal microbiome comprises
Fig. 1. Advantages of topical vaginal therapy in the era of antimicrobial resistance.
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nated by a lactobacillus (lactic acid–producing) species: Lactobacil-
lus crispatus, L. gasseri, L. iners, or L. jensenii. Predominantly, L.
crispatus was detected in healthy vagina, whereas L. iners domi-
nated the flora prior to BV [16].
The hydrogen peroxide–producing lactobacilli are responsible
for a low-pH environment, thereof inhibiting bacterial growth.
Those lactobacilli contribute to 70 to 90% of the total microbiome
in a healthy vagina [13,17].
Recently, polymicrobial biofilms, the structured groups of bac-
teria adherent to vaginal tissues, have emerge as a major contrib-
utor to chronic infections and alarming recurrence levels [11].
Biofilms represent a rather well-structured architecture compris-
ing channels allowing nutrients circulation as well as divided areas
that may contain genetically identical cells exhibiting different
profiles of gene expression, as a consequence, the environment
becomes strongly hostile against antimicrobial molecules as well
as immune responses [18]. Virulence of bacterial biofilm can be
contributed to the production of extracellular polymeric sub-
stances (EPSs); EPSs decrease the penetration of antimicrobial
molecules through biofilms structure and reduce the action of
human immune response cells. The extracellular matrix consti-
tutes a physical barrier against all types of antibiotics [18].
2.2. Impact of STIs on women’s health in the era of antimicrobial
resistance
The effect of vaginal infections on woman’s quality of life varies
from personal experiences to health care costs related to the man-
agement of vaginal infections, as well as adverse reproductive
health consequences [13]. Genital infections comprising STIs,
endogenous infections such as vulvovaginal candidiasis (VVC), BV
or aerobic vaginitis (AV) and healthcare-associated infections are
raising serious concerns in era of AMR [19]. The infection-related
complications in pregnant women may lead to premature rupture
of membranes, miscarriages and premature birth [20]. It is
important to consider that geographically, the resistance to STIs3
treatment can vary, for example, in Taiwan the resistance to tetra-
cycline and erythromycin was found higher than in other regions
of the world, while the resistance rate for levofloxacin was rela-
tively lower [20]. Recent study conducted in Poland [19] indicated
the highest resistance in S. agalactiae, namely the macrolide-linco
samide-streptogramin B mechanism was identified in 38.6% of
strains. It is important to highlight that the antibiotic consumption
in Poland is much higher than the European average. Recent study
conducted in Eastern Sicily revealed that S. agalactiaewas the main
pathogen responsible for early- and late-onset infections over the
past 5 years [21].
The World Health Organization (WHO) periodically estimates
health burden of four of the most common STIs: chlamydia
(Chlamydia trachomatis), gonorrhea (Neisseria gonorrhoeae), tri-
chomoniasis (Trichomonas vaginalis) and syphilis (Treponema pal-
lidum) [22]. In 2016, estimated 376 million new infections of
these four STIs were reported [23], corresponding to 1 million STIs
per day, an alarming number [24]. In 2018 in the United States
alone, more than 67 million prevalent and 26 million incident STIs
were estimated, wherein chlamydia, trichomoniasis, genital her-
pes, and human papillomavirus (HPV) comprised 97% of all preva-
lent and 93% of all incident STIs [25].
Estimated 70% of all women will suffer from vaginal infections
during their lifetimes, where VVC and BV are the most prevalent
infections. Their treatments are hampered by high rates of resis-
tance and recurrence, high probability of complications, and nega-
tive effects on the vaginal microbiota [12,13,26]. Trihomonas
vaginalis is the most common nonviral STIs in the world [27].
The infection increases the risk of acquisition of other STIs, includ-
ing human immunodeficiency virus (HIV) by almost three-fold but
is considred curable.
BV is considered to be a polymicrobial disorder of the vaginal
microbiome that is marked by the absence of vaginal lactobacilli
[28]. Although it is rather challenging to estimate its real preva-
lence, estimates suggest that the rates are about 15% among preg-
nant women, 20 to 25% among young women, and up to 30 to 40%
among women attending sexually transmitted disease clinics. BV
Fig. 2. Antimicrobial resistance identified in gonorrhea, mycoplasma and chlamydia (Based on references in respective chapters on nanoformulations). (as per March 2021).
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quantitatively [13]. Moreover, BV is considered a biofilm infection,
with a dense polymicrobial biofilm consisting primarily of Gard-
nerella vaginalis adhering to the vaginal epithelium. The strong
polymicrobial biofilm reportedly present in 90% of women with
BV and the high levels of drug-resistance found in G. vaginalis clin-
ical isolates are considered major contributors to therapy failure
[12]. Higher bacterial loads of G. vaginalis creates a favourable envi-
ronment for Atopobium vaginae, further contributing to increased
biofilm formation. Consequently, the biofilm creates a favorable
anaerobic environment for other obligate anaerobic bacteria [29].
It is estimated that half of women with BV also have a BV–associ-
ated biofilm. However, better mechanistic insight on the direct link
between biofilm and diseases is needed [30]. Women with BV
exhibit a significant increase (1000x) in potentially virulent bacte-
ria as compared to healthy woman [13]. BV is associated with both
the acquisition and transmission of other STIs, especially HIV.
Interestingly, the vaginal microbiome exhibited in women infected
by BV, especially G. vaginalis, inactivates the topical microbicide
tenofovir, widely used in the prevention of HIV transmission
[31]. BV is also strongly linked to C. trachomatis infection.
Desquamative inflammatory vaginitis is a newly acknowledged
clinical syndrome characterized by persistent purulent vaginal dis-
charge and vaginal erythema, often with submucosal cervicovagi-
nal petechiae [13]. Since the inflammation is the cardinal feature
of this disorder, literature, although limited, often reports the term
idiopathic inflammatory vaginitis [32]. The vagina becomes colo-
nized with facultative bacteria, typically comprised of Escherichia
coli, Staphylococcus aureus, group B streptococcus, or Enterococcus
faecalis.
2.3. Threatening multidrug resistant STIs
To discuss the urgent need to treat increasing threat of STIs with
limited treatment options, we attempted to categorize them based
on the severity of the current resistance status. We are aware that
the severity can also be categorized by the prevalence of a disease
or available treatment options. We therefore propose the following
severity ranking for three STIs with serious resistance against con-
ventional treatment (Fig. 2).
2.3.1. Neisseria gonorrhoeae
In the current era of AMR, gonorrhea emerged as a priority
pathogen [24]. It is caused by the bacterium N. gonorrhoeae; and
is currently the second most common bacterial STI with an esti-
mated yearly burden of 87 million cases worldwide [23]. Concomi-
tant infections of N. gonorrhoeae with C. trachomatis, T. vaginalis
and M. genitalium will occur in almost 30% of cases. Unsuccessful
treatment may lead to pelvic inflammatory disease, ectopic preg-
nancy and infertility [24]. The choice of antimicrobials that can
be used for treatment of gonorrhea is very limited, since resistance4
has even been reported to extended spectrum cephalosporins,
which are currently recommended antimicrobial therapy. The first
gonococcal isolates exhibiting ceftriaxone resistance as well as
high-level azithromycin resistance were confirmed in England
and Australia in 2018 [33]. After failures of dual-antimicrobial
therapy approaches currently used to treat the infection, new
antimicrobials, vaccines, novel technologies as well as diagnostic
tools, repurposing of antimicrobials (spectinomycin, gentamicin,
fosfomycin, and ertapenem) have been suggested as approaches
to tackle the disease challenges [34–35].
2.3.2. Mycoplasma genitalium
M. genitalium is a bacterial STI linked to urogenital inflamma-
tion and symptoms in both sexes. Since M. genitalium is not a
reportable illness, accurately assessing its prevalence and inci-
dence is challenging [27]. Untreated infection can lead to cervicitis,
pelvic inflammatory disease, preterm birth, spontaneous abortion,
and infertility in women [36,37]. Its therapy is hampered by
rapidly rising levels of resistance to azithromycin and moxifloxacin
[27]. In a recent study in Nordic countries (except Island) macro-
lide and fluoroquinolone resistance-associated mutations were
detected in 17.7% to 56.6% and 4.1% to 10.2% ofM. genitalium infec-
tions, respectively [38]. Azithromycin resistance-associated muta-
tions were identified in 57.0% ofM. genitalium-positive participants
[39]. Khosropour and co-workers [37] found that nearly all M. gen-
italium strains attested in Seattle, USA, exhibited a macrolide resis-
tance mutation indicating a high previous exposure to
azithromycin. Consequently, M. genitalium may become untreat-
able STI. Moreover, the infections are disproportionally affecting
sexual and racial/ethnic minorities and socioeconomically chal-
lenged populations [27]. Pitt and co-workers [40] investigated
the prevalence of AMR-conferring mutations in M. genitalium
among the sexually active British general population and reported
16.1% macrolide resistance-conferring mutations and 3.3% fluoro-
quinolone resistance-conferring mutations. High prevalence of
coinfection of azithromycin-resistantM. genitaliumwith other STIs,
especially Chlamydia trachomatis has been reported [36].
2.3.3. Chlamydia trachomatis
Although the evidence that AMR is the reason behind unsuc-
cessful treatment of C. trachomatis by conventional therapy
remains a topic of discussion, there are rather clear proofs of
in vitro heterotypic resistance to conventional antibiotics at high
levels of organism load. A continuous rise in AMR is expected to
further limit the available therapy [36,41–43]. C. trachomatis infec-
tions are often asymptomatic, and the reported number of 130 mil-
lion new infections a year, is believed to be considerably
underestimated [22]. Untreated infections can cause serious com-
plications such as pelvic inflammatory disease, ectopic pregnancy,
tubal infertility, preterm birth and increased risk of HIV transmis-
sion. Novel formulations for known antibiotics, novel antimicrobial
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approaches for successful therapy.
3. Assuring efficient localized drug therapy
3.1. Understanding the challenges nanomedicine faces at vaginal site
Vagina as a site for drug administration and therapeutic effect
bears unique challenges that need to be both understood and con-
sidered when designing and developing formulation destined for
this site ½3–9]. For nanomedicine to overcome the obstacles associ-
ated with the delivery of nanomedicine-associated drugs or active
ingredients to vagina, careful tailoring of nanoformulation is a pre-
requisite. In particular, an interplay between the vaginal environ-
ment and nanocarriers’ features need to be tweeted [8,44]. Some
of the challenges are widely discussed in the literature, whereas
other remain rather neglected.
One of the first challenges to consider is the residence time of
the nanomedicine at vaginal site in spite of vaginal clearance and
discharge. The mucoadhesive delivery systems were originally sug-
gested to assure prolonged residence time within vaginal cavity
[4]. However, the challenge was rather more complex than antici-
pated. To address the potential of mucoadhesiveness, it is impor-
tant to gain deeper insight on the role of mucosa and mucus. The
surface of mucosal sites, including vaginal, comprises nonkera-
tinized epithelium forming a most stringent hurdle to molecular
and particle permeability/transport. This barrier exhibits selective
permeability to both small molecules (e.g., water and ions) as well
as large, supramolecular structures such as microorganisms, sper-
matozoa or nanoparticles [45]. The mucosal barrier is rather vari-
able and highly dependent on specific functions related to
mucosa location. In addition, enzymatic activity as a barrier to drug
needs to be considred at the mucosal tissue. Although vaginal siteFig. 3. Schematic summary of nanosystems propo
5
does not exhibts equally strong enzymatic activity (in comparison
to gastrointestinal tract) it has to be considred. The mildly acidic
pH can hamper efficient drug delivery in the vagina. More detailed
discussion on mucosa as a barrier to drug delivery, including the
interaction between mucin fibers and nanoformulations can be
found in the recent review by das Neves et al. [45]. Moreover,
mucins interactions render the formation of a natural gel with vari-
able viscosity and limited homogeneity. Vaginal mucosa responds
to sexual stimulations and may change in viscosity and ‘‘wetness”.
Moreover, the change may affect the drug release from formulation
applied intravaginally [46]. The role of mucoadhesiveness was
challenged by the proposed role of the mucus-penetrating vehicles
[47]. Regardless of the mucoadhesion or mucus-penetration, to
achieve efficient localized drug effect, released drug needs to
evenly distribute throughout the vaginal environment, often
referred as pharmacokinetic functioning, to render its therapeutic
action or pharmacodynamic functioning. Released drug overcom-
ing dilution and barriers can reach the epithelium, underlying
stroma and beyond [44]. Katz et al. [44] proposed simplified
multi-compartment model comprising an interplay between the
features of the delivery system, ambient vaginal fluid, semen,
epithelium, stroma and the bloodstream, if systemic absorption
takes place. However, the model requires additional complexity
to address a challenge of nanoparticle shape, symmetry and soft-
ness/hardness on the elastic deformation of the mucus gel. In a
recent review by das Neves and colleagues [45] the authors
addressed the limitations of currently available models that mostly
focused on the mucus-penetration or mucoadhesiveness of drug
nanocarriers regarding pharmacokinetic performance without suf-
ficient comprehensive understanding of molecular, physicochemi-
cal and mechanical interactions.
Vaginal discharge is additional challenge; it is a rather complex
mixture of epithelium transudates, cervical mucus, exfoliatingsed for topical therapy of vaginal infections.
Fig. 4. Classification of nanoparticles, modified from [4] (Permission from Copyright Clearance Center, Elsevier).
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leukocytes, endometrial and fallopian’ tubes fluids. It comprises
enzymes, enzyme inhibitors, proteins, carbohydrates, amino acids,
glycoproteins, lactic acid, acetic acid, glycerol, urea, glycogen and
various ions [48]. The volume and composition of vaginal fluid
are affected by the stages of the menstrual cycle, hormones and
sexual arousal [49].
The drugs will both diffuse faster through the vaginal fluids and
disappear from the luminal fluids than from the underlying tissue.
Diffusion and penetration of particles can be tailored by the parti-
cle size and surface properties. The size regulates the ability to fit
into the mesh pores within mucin fibres while the surface proper-
ties control the interaction between the nanoparticles and mucin
[5]. Utilizing polyethylene glycol (PEG) for PEGylation, the fate of
NPs can be tuned to desired distribution [50].
The use of vaginal pH as an indicator of possible infections as
well as pre-/post-menopausal status has been widely discussed
[8,45,51]. Rather limited scientific data are available on the effect
of overuse of hygienic products on the natural vaginal pH which
serves as a first defense against microbial infections [8]. Candidia-
sis and BV elevate the vaginal pH above pH 5 due to reduction of
Lactobacilli population [52]. Rather limited attention has been
given to the effect of prolonged use of oral contraceptives or hor-
mone replacement on the changes in vaginal pH and membrane
thickness [53].3.2. The role of nanomedicine in assuring localized drug therapy
This review focusses on utilization of nanomedicine for topical
therapy of vaginal infections. Different type of nanoformulations
have been proposed as vehicles for improved delivery of active6
ingredients to vaginal site. The types of nanomedicines (nanophar-
maceuticals, nanoformulations, nanosystems, nanoparticles,
nanocarriers) that are discussed in this review are schematically
summarized in Fig. 3.
3.2.1. Overview of nanoformulations
The nanoformulations can be categorized in various manners,
however, based on their ability to remain within vaginal cavity
and permit the delivery of active molecules into the deeper epithe-
lium, we propose, in Fig. 4, the classification based on both origin
and surface characteristics relevant for system’s mucoadhsiveness
versus mucopentration.
In summarizing the reported data on nanomedicine for vaginal
therapy of infections, we have mostly focused on classification
according to the material used for nanoformulations. We also pri-
oritized the type of nanocarriers which were more extensively
studied.3.2.2. Lipid-based nanoparticles
3.2.2.1. Liposomes. Liposomes are phospholipid-based nanovesicles
consisting of one or more concentrically arranged bilayers enclos-
ing inner aqueous compartment(s) (Fig. 4). Structural properties of
liposomes allow entrapment/incorporation of drugs differing in
molecular weights and lipophilicity. Their functionalization per-
mits tailoring for different routes of drug administration [54–56],
however, in comparison to their application via parenteral and
(trans)dermal routes, their potential in vaginal therapy has been
reported relatively late [57,58]. Liposomes can be classified as con-
ventional and elastic vesicles including deformable liposomes,
propylene glycol liposomes, and deformable propylene glycol lipo-
somes (DPGLs) [4]. More than 50% of all the investigations on the
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liposomes. Elastic liposomes consist of phospholipids and the edge
activators, i.e., single-chain surfactants (deformable liposomes),
and/or polyols (propylene glycol) contributing to the bilayer flexi-
bility [4].
The liquid nature of liposomes and leakage from the application
site is considered their limitation as potential formulation for vagi-
nal site, that can be overcome by:
i) coating/incorporating mucoadhesive polymers, such as chi-
tosan, within liposomes [59,60],
ii) incorporation of liposomes within semisolid mucoadhesive
vehicle, such as hydrogel [61–67], or
iii) embedding liposomes into solid vehicle, i.e. tableted pre-
liposomes [68].
The issue of liquid nature and need for secondary vehicle to pro-
long their residence time at vaginal site is not unique to liposomal
suspensions and applies to different nanocarriers suspensions dis-
cussed in the review.3.2.2.2. Solid lipid nanoparticles. Solid lipid nanoparticles (SLNs) and
nanostructured lipid carriers (NLCs) are often found superior to
liposomes for industrial scale manufacturing. SLN, made of solid
lipids at room temperature, are spherical particles, accommodating
a drug or active molecules between fatty acid chains or attached to
the carrier matrix surface [69,70]. SLNs comprise surfactants which
serve as stabilizing agents (Fig. 4). NLCs lipid core comprises a mix-
ture of solid and liquid lipids, acting on improved stability [71,72].
Since vaginal mucosa is preferable environment for more hydro-
philic vehicles, the evaluation of SLNs and NLCs in localized vaginal
therapy remains limited. The studies are discussed in respective
diseases overview.3.2.2.3. Liquid crystals. Lipid crystals are unique structures com-
prising lipids that flow like liquids but maintain the structural
characteristics of crystalline solids. Although they do not transfer
directly from the liquid to solid state, under certain conditions lipid
crystals exhibit molecularly organized intermediate phases (me-
sophases) with both liquid and solid properties, i.e. liquid crys-
talline phases. They have attracted considerable attention as drug
delivery system enabling sustained release and protection of
embedded sensitive drugs [73,74]. Moreover, their malleable
structure allows easiness of topical application, including vaginal
route of administration [75].3.2.3. Polymeric nanoparticles
Polymeric NPs can be built of natural and synthetic polymers.
Considering the biocompatibility and safety in regard to vaginal
administration, the number of NPs build from synthetic polymers
is rather limited [3]. The polymers poly-D,L-lactic acid (PLA),
polyglycolic acid (PGA), poly(lactic-co-glycolic acid) (PGLA), poly-
e-caprolactone (PCL), and poly(methylmethacrylate) (PMM) are
considered safe for human use [76]. Due to extensive research
efforts to develop safe and efficient microbicides against HIV, NPs
proposed as microbicides dominate the literature (e.g. [77–79]).
Moreover, a single NPs for combination of antiretroviral agents
were also proposed [80,81]. Mucoadhesive NPs based on the natu-
ral polymer carrying tenofovir enabled a controlled release of this
drug [82]. More polymeric NPs are discussed in chapters focused
on the infection type the NPs were proposed for. We highlight here
the dendrimers, one of the most successful polymeric nanocarrier
destined for vaginal site, as well as nanofibers, emerging type of
nanoformulations.7
3.2.3.1. Dendrimers. Dendrimers are extensively branched poly-
meric macromolecules (nanoparticles) constructed through the
sequential addition of branching units radiating out from an initi-
ating point. Dendrimer comprise four major components: initiator
(core), branching units, linkers and surface groups [83]. Highly
branched 3D structure permits a high degree of surface functional-
ity and ability to incorporate various drugs and active molecules
(inside or on the periphery of dendrimer). The advantages of den-
drimers consider their water solubility, defined molecular weight,
nanometer size range (typically 5–20 nm) and narrow polydisper-
sity, allowing easier transport across the biological barriers. The
most studied dendrimers are based on poly(amidoamine), poly
(propylene imine) and L-lysine, while novel approaches include
hybrid dendrimers based on the assembly of dendrimers with
NPs [84,85].
3.2.3.2. Nanofibers. Nanofibers are fiber shaped porous polymeric
nanostructures, wherein two of their dimensions are in nanoscale.
They are characterized by high surface area-to-volume ratio and
ability to incorporate various pharmacologically active ingredients
[86,87]. Mechanical properties, in addition to their large surface
area, as well as solubility, stability, ability to be manufactured ster-
ile, and potential for controlled drug release at different pH condi-
tions, offer unexplored advantages as novel transmucosal
nanoformulations [88].
There are other different types of nanocarriers which did not
gain widespread attention such as inorganic NPs (silver, gold),
micelles and similar (Fig. 3). Those are discussed in the chapters
dealing with the respective infections.
However, considering the surface properties of NPs and their
interaction with vaginal mucosa as a barrier to drug delivery, we
separately address their interaction with vaginal mucus in section
3.3.
3.3. Mucoadhesive and mucus-penetrating NPs
Numerous work has been published on mucoadhesive formula-
tions for vaginal delivery, especially mucoadhesive polymer-based
formulation [10]. However, Lai et al. [89] challenged this concept
questioning the ability of mucoadhesive nanocarriers to reach dee-
per epithelial layers, where the infection mainly resides. Utilizing
viruses as biomodel, viral-like nanoparticles become widely stud-
ied NPs [4]. Experimental evidence proved that densely PEGylated
large NPs (200–500 nm), diffused readily through undiluted
human cervicovaginal mucus, unlike corresponding particles of
smaller size (100 nm) due to the pore sizes within the mucus
[89]. Moreover, it was proven that PEG-PLGA NPs (100 nm) with
a neutral surface rapidly diffused through fresh, undiluted cervico-
vaginal mucus [90]. Ensign et al. [91,92] followed PEG-PLGA and
polystyrene mucus-penetrating NPs through mouse cervicovaginal
mucus in different medium and concluded that NPs in hypotonic
solution penetrated deep into the vaginal folds within minutes
and remain there for 24 h, whereas conventional NPs were cap-
tured in the thick mucus layer unable to reach the deeper tissue.
These findings suggest that mucus-penetrating PLGA NPs, particu-
larly PEG-PLGA, are safe and effective for the prevention and treat-
ment of STIs [91,92]. Understanding the interplay between NPs and
mucus (Fig. 5) while maintaining the native barrier of epithelium
opens up a possibility to optimize the nanocarrier penetration into
deeper layers [91–93].4. Proposed nanomedicine to treat specific vaginal infection
We organized presenting the nanoformulations according to the
urgent need to improve the therapy due to alarming AMR issues
Fig. 5. Schematic drawing of interplay between formulation and vaginal mucus as presented for gel, conventional nanoparticles (CP) and mucus-penetrating nanoparticles
(MPP). Adapted from Ensign et al. [92]. (Permission from Copyright Clearance Center, Elsevier).
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ment of gonorrhea.
4.1. Nanomedicine for the treatment of Neisseria gonorrhoeae
4.1.1. General considerations
Gonorrhea emerged as a major public health concern with an
estimated global incidence of 86.9 million annually [94]. Infections
caused by N. gonorrhoeae are often asymptomatic, and due to
anatomical differences, infections are more complicated to diag-
nose in women [95]. N. gonorrhoeae is gram-negative, human obli-
gate bacteria which pathogenesis involves transmission,
adherence, colonization and invasion, ending in immune evasion
(Fig. 6).
Initially,N. gonorrhoeae adheres to host epithelial cells of vaginal
mucosa, replicates and forms microcolonies, subsequently entering
the cells by transcytosis. Invasion triggers the release of inflamma-
tory cytokines and chemokines, recruiting neutrophils that interact
with the bacteria forming a purulent exudate that facilitates the
transmission ofN. gonorrhoeae [96].N. gonorrhoeae generally causes
mucosal vaginal tract infection; however, it can also attach to the
epithelium of the ectocervix. Untreated or unsuccessful treatment
of infection can ascend and cause serious complications as well as
increased transmission risk of other STIs [94]. Oral or intramuscular
administration of antibiotics is the first-line treatment; however, N.
gonorrhoeae is rapidly developing resistance to every major class of
antibiotics and even dual treatment often fails [9]. The recom-
mended therapy is currently antibiotics ceftriaxone and azithromy-
cin (AZT), generally as dual therapy [35]. However, the
susceptibility is rapidly decreasing globally [97].
4.1.2. Choice of nanoformulation
Considering that Neisseriaceae bacteria has been co-evolving
with its human host for centuries [94], the introduction of
nanomedicines for the localized treatment of N. gonorrhoeae infec-
tion is rather recent. To our knowledge, the first nanoformulation
for vaginal delivery targeting N. gonorrhoeae infection was a
liposome microbicide formulation developed by Wang et al. [98].
The in vitro effect of liposomal formulation containing octylglyc-
erol was compared to the microbicide effect of plain Carbopol
hydrogel containing octylglycerol. Liposomal octylglycerol formu-8
lation expressed a superior activity against N. gonorrhoeae com-
pared to the conventional gel formulation; the activity was
maintained for at least two months. In vivo safety evaluations in
macaque model by rectal application, confirmed its safety. More-
over, ex vivo penetration studies on human ectocervical tissue
demonstrated the lack of octylglycerol penetration, confirming
localized effect. No toxicity was inflicted to the freshly excised
ectocervical tissue [98].
The natural-origin polymer chitosan is shown to exhibit signif-
icant intrinsic antimicrobial activity [99], to efficiently disrupt
vaginal biofilms [100] and is therefore considered highly attractive
in the development of vaginal delivery systems. The potential of
chitosan NPs (CNPs) in the localized treatment of N. gonorrhoeae
has been recently evaluated in vitro [101]. The anti-gonococcal
effect of CNPs was confirmed and shown effective against the
strains with high-level resistance against commonly used antibi-
otics. Several mechanisms of antimicrobial action of chitosan were
proposed, such as the interaction with cellular surface, interaction
with targets within the cell, and antimetabolite action [102]. The
antimicrobial activity of CNPs was clearly influenced by the intrin-
sic, environmental and microbial factors [103], however, the exact
mechanisms is not yet known. The study by Alqahtani and col-
leagues indicated that the pH highly influenced the activity of
CNPs; a superior antimicrobial effect was seen at pH 5.5, however,
it was also expressed at neutral pH. Moreover, CNPs were con-
firmed to be non-toxic [101].
Li et al. [104] evaluated carbon nanotubes, silica, zinc oxide, and
silver nanoparticles (AgNPs) for their anti-gonococcal activity
in vitro. Standard N. gonorrhoeae strains were challenged against
the nanomaterials of various particle size. A superior activity was
seen for the 120 nm AgNPs. Several mechanisms for the antimicro-
bial activity were suggested, including the disruption of the cell
membrane, induced production of reactive oxygen species (ROS),
and disruption of DNA replication [105–107], however, the exact
mechanism remains unclear. Further, the combination of AgNPs
and cefmetazole, an antibiotic that is commonly ineffective
towards N. gonorrhoeae, was challenged against resistant clinical
isolates. Estimated MICs showed an increased effect of the antibi-
otic when in combination with the NPs [104]. In a more recent
study, the anti-gonococcal effect of silver nanoclusters (AgNCs)
was evaluated in vitro [108]. The AgNCs were coated with
Fig. 6. Stages of Neisseria gonorrheae infection and targets for nanomedicines (green arrows). 1) N. gonorrheae adheres to epithelial cells then replicates and forms
microcolonies. Nanoparticles can act as microbicides and avoid bacterial adhesion. 2) Bacteria crosses the epithelial barrier by transcytosis. Nanoparticles can act as
microbicides and prevent bacterial colonization and invasion of epithelium. 3) N. gonorrheae is phagocytosed by macrophages and causes production of inflammatory
cytokines and chemokines. Interaction with dendritic cells modulate apoptosis and also causes the release of inflammatory cytokines and chemokines. Nanoparticles can
enable effective treatment of infection and/or inflammation. 4) Neutrophils are recruited to the infection site where they interact with and phagocytose N. gonorrhoeae. 5)
Neutrophils migrate across the epithelium facilitating the transmission of N. gonorrhoeae. Nanoparticles can impair the bacterial transmission. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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strains were exposed to the MNBA-coated AgNCs and treatment
compared to commonly used antibiotic ceftriaxone. A
concentration- and time-dependent effect was seen for both
MNBA-coated AgNCs and the antibiotic, however, the antibacterial
effect of MNBA-coated AgNCs was superior to ceftriaxone. The
study showed that the nanoformulation could effectively kill mul-
tidrug resistant N. gonorrhoeae within 1 h also at high level of
organism load. Moreover, no in vitro toxicity was found [108].
In addition to the search for novel treatment options, the pre-
vention of infection is of importance. The development of vaccines
for multidrug resistant N. gonorrhoeae has resulted in four clinical
trials, of which all failed to provide adequate protection from infec-
tion [109].4.2. Nanomedicine for the treatment of Mycoplasma genitalium
4.2.1. General considerations
M. genitalium is an emerging sexually transmittedbacterial infec-
tion that is highly prone to the development of AMR [110,111]. M.
genitalium is transmitted by direct mucosal contact and infections
are often asymptomatic [112]. The life cycle of M. genitalium and
the mechanism by which it causes inflammation and cellular dam-
age is unknown [113]. However, infection can cause serious compli-
cations in women, such as pelvic inflammatory disease, cervicitis,
preterm birth and spontaneous abortion [114].
M. genitalium was first isolated in 1981 and described as a
mycoplasma [113]. Due to the lack of a peptidoglycan-containing9
cell wall, antibiotics that target the cell wall are ineffective against
the pathogen and options of antibiotic treatment is limited [110].
Moreover, M. genitalium can easily develop single-nucleotide poly-
morphisms that can lead to AMR [115]. Currently the macrolide
AZT is recommended as a first line, and the fluoroquinolone mox-
ifloxacin as a second line treatment [116]. However, the prevalence
of macrolide and fluoroquinolone resistance is rapidly increasing.
M. genitalium is evolving into a superbug that is immensely diffi-
cult to treat, or even untreatable [116,117].4.2.2. Choice of nanoformulations
To our knowledge, the use of nanomedicine has so far not been
explored for improved therapy of vaginal M. genitalium infections.
The need for new treatment options is evident [118] and nanome-
dicine can be an important tool to better understand the pathology
of M. genitalium and identify promising strategies to better tackle
the challenges of AMR. Advanced delivery systems have the poten-
tial to provide improved efficacy of currently used antimicrobials
as well as intensify the potential of alternatives to existing
antibiotics.4.3. Nanomedicine for the treatment of Chlamydia trachomatis
4.3.1. General considerations
With more than 127 million new infections reported globally
each year, C. trachomatis is a major cause of bacterial STIs [22]; it
is particularly prevalent in young females with a four times higher
infection rate compared to the general population [119]. Genital
Fig. 7. The chlamydia life cycle and possible targets for nanomedicines (green arrows). 1) Elementary body, the infectious form of C. trachomatis, attaches to a host cell and is
phagocytized ending up in a vacuole called inclusion. Nanoparticles can act as microbicides and avoid bacterial cell entry. 2) Immune cells activate the production of
inflammatory cytokines and chemokines. Nanoparticles can enable effective treatment of inflammation. 3) Elementary body reorganizes to reticulate body. 4) Reticulate
bodies replicate, producing several reticulate bodies within the inclusions. Nanoparticles can enable effective treatment of infection. 5) The reticulate bodies start to convert
back to elementary bodies. 6) Infectious elementary bodies are released from the cell. Nanoparticles can impair the bacterial transmission. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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toms in approximately two-thirds of women, and the reported
number of infections is considered substantially underestimated.
C. trachomatis is a small obligate intracellular, gram-negative bac-
terium with a complex biphasic life cycle (Fig. 7).
The bacterium exists in two forms; the infectious elementary
body and non-infectious reticulate body. Elementary bodies enter
the host cells and differentiates to reticulate body that replicates
within an inclusion, concealing its antigenic profile from the
immune system. The reticulate bodies start to convert back to ele-
mentary bodies and move between the hosts in the non-replicative
form [120]. Oral antibiotics are available for the treatment of C. tra-
chomatis; however, they are efficacious only when administered at
an early stage of infection, and clinical failure and recurrence rates
are high [121]. The lack of treatment or its failure, due to asymp-
tomatic infections, affect the public health burden by favoring
the onset of severe complications [122]. Moreover, persistent
C. trachomatis infections enhance the risk of HIV transmission.4.3.2. Choice of nanoformulation
Liposomes were the first and are most studied delivery system
proposed for the treatment of chlamydia. However, dendrimers,
PLGA NPs and other nanoformulations were also tested. Interest-
ingly, natural origin substances such as resveratrol, were also pro-
posed as alternative to antibiotic. Report on nanomedicines
developed for the delivery of antibiotics targeting C. trachomatis
was, to our knowledge, first published in 1992. The ability of10liposomal tetracycline to inhibit the propagation of C. trachomatis
in McCoy cells was evaluated [123]. McCoy mouse fibroblast is
the commonly applied cell line for studying chlamydial infections
under in vitro conditions [124–126]. Chlamydia infected cells were
exposed to free tetracycline and tetracycline incorporated into
cationic, anionic and neutral liposomes, and incubated for 48 h.
When compared with free tetracycline, neutral liposomes contain-
ing tetracycline were the most efficient for inhibiting the growth of
C. trachomatis [123]. In another early study, tetracycline and doxy-
cycline were incorporated separately into cationic, anionic and
neutral liposomes to evaluate the anti-chlamydial activity in vitro
[127]. The results showed that the anti-chlamydial effect increased
for both tetracycline and doxycycline when in liposomal formula-
tion. Moreover, the ability of formulations to prevent the formation
of inclusions after a second passage was evaluated. The superior
activity of liposomally entrapped antibiotics was confirmed
[127]. In further study, Sangaré and colleagues challenged liposo-
mal doxycycline prepared as intramuscular injection against
chlamydia infection in vivo [128]. Doxycycline was incorporated
into cationic liposomes and injected into progesterone-treated,
female mice infected with C. trachomatis serovar L2; two days
post-infection the treatment group were injected with the free
and liposomal doxycycline (10 lg/g body weight) for 3 or 7 consec-
utive days. Results showed that the infection rates were lower in
all treatment regimens compared to untreated mice, however,
there were no significant difference in the free doxycycline and
liposomal doxycycline treatment. In conclusion, the 7-day
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tective against ascending chlamydial genital infection in mice
[128]. Although not an example of localized drug therapy, the work
is important to understand the potential of nanosystem to enhance
potency of antibiotics.
Azithromycin (AZT) is a broad-spectrum macrolide commonly
administered orally as C. trachomatis therapy, however, it is con-
traindicated during pregnancy as well as associated with subse-
quent side effects, clinical failure and high recurrence rates [129].
The localized delivery of AZT to the site of action at lower doses
can prevent systemic antibiotic effects and reduce the side effects.
Moreover, the risk of developing AMR can be reduced by the local-
ized therapy. Recently, Vanić and colleagues developed AZT lipo-
somes with varying bilayer elasticity and surface charge, to
evaluate the effect of AZT in nanoformulations against C. trachoma-
tis infection in vitro [130]. HeLa 229 cells were infected with C. tra-
chomatis serovar D and exposed to free AZT and liposomal AZT.
After 48 h of incubation, deformable propylene glycol liposomes
(DPGLs) containing AZT was found the most promising among
the liposomal formulations tested toward C. trachomatis. All liposo-
mal formulations containing AZT expressed a lower efficacy com-
pared to the free AZT. However, a free drug exhibited a high
penetration through the vaginal tissue ex vivo, suggesting that an
undesirable systemic effect can occur. Antibiotic treatment for
pregnant patients suffering from vaginal infections is limited;
assuring the efficient topical effect while avoiding systemic
absorption is considered the best therapy option. Liposomal AZT
enabled a retention on top and within the vaginal tissue, demon-
strating the potential of liposomal AZT in the localized vaginal
therapy. Moreover, DPLGs was found to express the strongest
potential for the eradication of biofilms [130]. The ability of lipo-
somes to enhance the delivery through the formed biofilms can
generate a high local concentration of AZT, improving the thera-
peutic potential of the developed delivery system.
The disturbance of microbiota or the absence of Lactobacillus
spp, caused by bacterial vaginosis, is associated with an increased
risk of acquiring STIs, including C. trachomatis. [119]. Employing
natural origin substances with multi-targeted pharmacological
properties might be valuable tools to tackle AMR [67,131]. The
liposome-in-hydrogel delivery system containing resveratrol
(RES) for the localized treatment of C. trachomatis has been
recently evaluated in vitro [126]. RES is poorly water-soluble and
has rather limited stability, by liposomal entrapment, the solubility
improved while the substance was protected from environmental
and chemical changes. RES is naturally occurring polyphenol
exhibiting many potential health benefits, and a wide range of bac-
terial, viral and fungal species are known to be susceptible to RES,
including C. trachomatis [124,132]. McCoy cells were infected with
C. trachomatis serovar E. Two hours post infection, the infected cells
were exposed to free RES, liposomal RES and RES liposomes-in-
hydrogel formulation and the effect on bacterial survival was eval-
uated by staining of C. trachomatis inclusions 48 h post infection.
RES formulations reduced the number of C. trachomatis-infected
cells, and RES liposomes-in-hydrogel expressed superior anti-
chlamydial activity in the lower concentrations, compared to free
RES [126]. The mechanism behind the antibacterial action of RES
is not yet fully established. Several mechanisms are proposed, such
as the inactivation of the efflux pump [133], inhibition of bacterial
type III secretion system [134,135] and prevention of cell entry by
covalently binding to the elementary body of C. trachomatis [136].
The superior effect of RES when in delivery system indicates the
need for a delivery system to assure successful therapy. Although
chitosan is known to exert intrinsic antibacterial activity [99], chi-
tosan hydrogel had no effect on the anti-chlamydial challenge on
its own [126].11Combination drug therapy can amplify the therapeutic effect of
existing antibiotics; the co-delivery of rifampicin and AZT using
polymeric NPs has been evaluated in C. trachomatis therapy
in vitro [137]. NPs comprised biodegradable PLGA polymer, con-
tained two antibiotics either encapsulated separately or in a com-
bination. McCoy cells were infected with C. trachomatis serovar K
and exposed to free and PLGA encapsulated drugs immediately,
24 or 48 h after infection. When treated immediately after infec-
tion, no difference in MIC50 was seen for free drug vs NPs. However,
when treatment was introduced after 24 or 48 h, the encapsulation
in PLGA NPs improved the effectiveness of both drugs. The co-
delivery of antibiotics expressed a superior anti-chlamydial effect
compared to individual drugs. Toti et al. [137] proved that PLGA
NPs can efficiently accumulate in C. trachomatis inclusions and
improve the effectiveness of drugs when in delivery system.
Efficient localized delivery of microbicide is another approach
of great importance for prevention of STI transmission, including
chlamydia infections. Recently, Yang et al. [138] investigated the
encapsulation of small interfering RNA (siRNA) in PLGA NPs, tar-
geting the knock down of platelet derived growth factor
receptor-b (PDGFR-b) to reduce vaginal C. trachomatis infection.
PDGFR-b is an important surface binding protein for C. trachomatis;
the PLGA encapsulated siRNA enabled a reduced entry of C. tra-
chomatis (serovar K) into McCoy cells as well as reinforcement of
the host cells defense against the bacteria.
Dendrimers have also been studied for the localized therapy of
genital chlamydia infections. Mishra et al. [139] developed den-
drimers for the sustained delivery of AZT to infected cells. AZT
was conjugated with the polyamidoamine (PAMAM) dendrimers
and the effect on acute and persistent C. trachomatis infection in
human bronchial epithelial cells evaluated in vitro. Infected cell
cultures were pulsed with labeled dendrimer for 1 h at 24 or
48 h post infection. The fluorescence microscopy confirmed that
the dendrimers clearly entered and accumulated in the inclusions.
Moreover, AZT-dendrimers reduced the size and number of inclu-
sions to a greater extent than free AZT, demonstrating the superior
antimicrobial effect of AZT when conjugated with PAMAM den-
drimers [139].
Dendrimers exhibit both intrinsic antiviral as well as microbi-
cide properties. Patton and colleagues developed gel formulations
containing the microbicide SPL7013 dendrimer to protect against
C. trachomatis infections in pigtailed macaque models. The pig-
tailed macaques were not protected from C. trachomatis infection
after treatment with a single dose of 3% SPL7013 [140]. Yet, both
formulated and unformulated SPL7013 have shown the ability to
protect against Herpes simplex virus type 2 infection in mouse
models [141,142]. The formulation of dendrimers in hydrogels
can offer the safe localized treatment of ascending genital infec-
tions in pregnant women avoiding adverse effects to the fetus
[143] and has the potential to improve local therapy of vaginal
infections.
C. trachomatis infection causes a continuous production of
inflammatory mediators leading to severe complications, there-
fore, the control and regulation of inflammatory responses is sub-
sidiary in successful therapy. Yilma et al. [121] developed silver
polyvinyl pyrrolidone (Ag-PVP) NPs and evaluated their effect on
inflammatory mediators triggered by C. trachomatis infection
in vitro. The NPs controlled inflammatory mediators and inhibited
cytokines and chemokines produced by the infected macrophages,
confirming the potential of Ag-PVP NPs as regulators of inflamma-
tory responses induced by C. trachomatis infection. Jøraholmen
et al. [126] confirmed the superior anti-inflammatory activity
RES when in liposomes-in-hydrogel formulation, suggesting that
RES liposomes-in-hydrogel bears potential in the treatment of
other types of vaginal infections and related inflammations.
Ž. Vanić, M.W. Jøraholmen, and N. Škalko-Basnet Advanced Drug Delivery Reviews 178 (2021) 113855Currently, there is no licensed vaccine for C. trachomatis. The
search for effective vaccines is intensifying; liposomes [144], poly-
meric NPs [145–151] and dendrimers [152] are some of the
promising candidates in the development of successful vaccines
preventing C. trachomatis infections.
4.4. Nanomedicine for the treatment of bacterial vaginosis
4.4.1. General considerations
Bacterial vaginosis (BV) is one of the most prevalent genital
infections commonly affecting women of reproductive age,
although it has also been reported in menopausal women. BV rep-
resents disbalance in normal vaginal microbiota, namely, an over-
growth of anaerobic bacteria including G. vaginalis, A. vaginae,
Mycoplasma hominis, Ureaplasma urealiticum, Mobiluncus spp., Bac-
teroides spp. and Prevotella spp. Simultaneously, healthy vaginal
microflora (lactobacilli) undergoes significant reduction/disap-
pearance [153]. Currently recommended treatment regimens rely
on both oral and local administration of metronidazole, clin-
damycin and/or tinidazol [154]. In the era of AMR, topical therapy
become a preferable approach due to higher local drug concentra-
tions and avoidance of antibiotic-related side-effects and resis-
tance [7,155]. However, BV treatment is often challenged by the
thick polymicrobial biofilm adhering to the vaginal epithelium
[156]. Conventional antibiotic therapy often fails to completely
eradicate biofilms [157]; thereof BV is characterized by a high rate
of relapse and recurrence [154]. In addition, the link between BV
and an increased susceptibility to STIs (particularly viral), sponta-
neous abortion, pre-term birth, pelvic inflammatory disease and
endometritis become evident [156]. The last three decades wit-
nessed an increased interest in vaginal nanomedicines for
improved treatment of BV [8].
4.4.2. Choice of nanoformulation
Most of the nanoformulations for topical BV therapy encapsu-
lated metronidazole, the most prescribed drug in standard (con-
ventional) BV therapy. Majority of the research focused on
liposomes (non-mucoadhesive and mucoadhesive), nanofibers,
polymeric NPs and dendrimers.
One of the first studies on liposomes in vaginal therapy has
focused on in vitro and in situ stability of metronidazole-
containing liposomes for the treatment of BV. Lecithin-based lipo-
somes (300–350 nm), bearing 6–8% metronidazole, were found
stable in buffers pH 4.5 and 5.9, mimicking pre- and post-
menopausal vaginal conditions. Burst release of metronidazole
was detected in the first hour, followed by the sustained release
in the following 23 h at low pH and the presence of cow vaginal
mucosa (in situ stability studies). Liposomes would therefore per-
mit a high initial and medium maintenance doses, a favorable
approach in BV treatment [158]. To improve the penetration of
liposomes into deeper mucosa assuring delivery of encapsulated
metronidazole, the same researchers assessed deformable lipo-
somes. Several edge activators including sodium deoxycholate,
Tween 80 and Span 80 were tested to optimize the composition
of deformable liposomes. Deformable liposomes comprising 15%
deoxycholate demonstrated enhanced permeation of metronida-
zole through the in vitro model of the epithelial barrier as com-
pared to conventional liposomes [159]. Further research efforts
have been directed towards development of the new elastic lipo-
somes with increased bilayer deformability, and increased drug
load. This has been achieved by addition of propylene glycol, acting
both as drug solubilizer and affecting bilayer elasticity. Thus,
deformable propylene glycol liposomes (DPGLs) containing 10%
(w/w) propylene glycol embedding sodium deoxycholate
entrapped 14 mg of metronidazole/mg of lipid compared to deform-
able liposomes prepared without propylene glycol (7 mg/mg lipid).12To assure the retention within vaginal cavity, liposomes were
incorporated into Carbopol 974P hydrogel. The in vitro release
studies at simulated vaginal conditions proved extended and
diffusion-based release, which was affected by bilayers’ fluidity.
Approximately 80% of metronidazole has been released from elas-
tic DPGLs [66], in comparison to 50% metronidazole from the con-
ventional liposomes, characterized by rigid membranes [64]. The
hydrogel vehicle both impaired the viscosity and favorably
enhanced the storage stability by maintaining their original size
distributions [62–64].
Prolonged retention of liposomes onto vaginal mucosa can be
also achieved by utilizing mucoadhesive polymers either as a coat-
ing on the liposomal surface or building block of liposomal bilayers
[59,160]. For instance, Andersen et al. [160] developed
metronidazole-containing chitosomes and pectosomes, i.e.
liposome-based vesicles comprising mucoadhesive polymer (chi-
tosan or pectin) both on the liposomal surface as well as in the
inner and outer aqueous phases of the vesicles. The mucoadhesive
polymer enabled retention at the mucosal site and increased
metronidazole encapsulation.
Alternatively, liposomal metronidazole could be applied to
vaginal site as a solid formulation. This novel approach encom-
passes the use of tablets of pre-liposomes powder that, upon con-
tact with vaginal fluid, disintegrate, subsequently forming
liposomes. For this purpose, pre-liposomes were prepared by
direct spray drying of dispersion containing soy lecithin, mannitol
and metronidazole, which were then mixed with the different
types of non-mucoadhesive and mucoadhesive (chitosan, pectin)
fillers and compressed into tablets. Such solid liposomal formula-
tion offered a unique synergy between the ability of liposomes to
solubilize poorly-soluble drugs and increased stability provided
by compressed solid formulations. In addition, all metronidazole
was associated with the spray-dried powder, not only the
liposomally-entrapped drug, leading to higher drug load [68].
Metronidazole has also been loaded in polyvinylpyrrolidone
(PVP) nanofibers. It was demonstrated that PVP concentration
influenced the size, mechanical and mucoadhesive properties of
the nanofibers. Regardless of the PVP concentrations, fast release
of metronidazole was obtained (greater than 95% within 2 h) due
to the hydrophilic nature of the polymer. In addition, ex vivo per-
meation studies performed on cow vaginal mucosa revealed
increased flux and permeability of metronidazole from the nanofi-
bers as compared to the gel or solution [88]. The liposomally-
entrapped drugs, in comparison to nanofibers, assured slower
release and limited permeation across the vaginal mucosa, the fea-
tures considered relevant in local vaginal therapy, especially con-
sidering pregnant patients [60,130,161].
Because BV is characterized by the diminished levels of lacto-
bacilli and increased pH of vaginal fluid (greater than 4.5), admin-
istration of lactic acid favorably affects the re-establishment of
normal vaginal microflora and BV treatment. Rajan et al. [162]
developed poly(ethylene glycol) (PEG) nanocarrier-based degrad-
able hydrogels for the controlled release of lactic acid. PEG-lactic
acid nanocarriers were prepared by covalent attachment of lactic
acid to 8-arm polyethylene glycol thiol (PEG-SH) which were then
crosslinked with 4-arm N-hydroxylsuccinimide functionalized
polyethylene glycol (PEG-NSH) to form nanocarrier-based hydro-
gel. The novel nanocarrier-based hydrogel enabled sustained
release of lactic acid over several days. In vitro antibacterial studies
against G. vaginalis showed complete bacterial growth inhibition
within 48 h.
Among the nanomedicines studied for topical BV therapy, the
dendrimers have indisputably showed superiority. Astodrimer
(also known as SPL7013), a L-lysine dendrimer with a polyanionic
surface charge developed by Starpharma Pty Ltd (Australia) was
shown to inhibit growth of bacteria associated with BV via a novel
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drimer acted by blocking the attachment of bacteria to cells
thereby inhibiting the biofilm formation [83]. Astodrimer was fur-
ther incorporated into mucoadhesive Carbopol gel to assure suffi-
cient retention in the vagina. In the Phase 2 clinical trial
performed on 132 women, once daily application of Astodrimer
1% gel was proven to be effective for treating BV. Moreover, the for-
mulation was shown to be safe and well-tolerated, acting only
locally [163]. The superiority of the Astodrimer 1% gel has recently
been confirmed in the Phase 3 clinical trial. Due to its innovative
mechanism of action and safety, Astodrimer 1% gel offers great
potential for therapy of recurrent BV, especially women who fail
to respond to conventional therapy, or are intolerant to existing
antibiotic therapy [164].
4.5. Nanomedicine for the treatment of aerobic vaginitis
4.5.1. General considerations
Aerobic vaginitis (AV) has been defined as a vaginal condition
that is distinct from BV that requires different clinical treatment.
It is characterized by a diminished dominance of Lactobacillus
and consequent presence of abnormal vaginal microflora compris-
ing aerobic, enteric commensals or pathogens like Group B Strepto-
coccus (S. agalactiae), Enterococcus faecalis, Escherichia coli and
Staphylococcus aureus [165]. Additionally, AV is accompanied with
variable levels of vaginal inflammation and deficient epithelial
maturation. The prevalence of AV is generally lesser than BV (typ-
ically 7–12%). Although both AV and BV share some common fea-
tures, there are clear differences between them. For instance, BV is
not accompanied by inflammation; vaginal tissue in AV is com-
monly thinner, red and edematous with possible small ulcerations.
pH can be significantly higher in AV, and vaginal fluid is thicker,
commonly yellow or green colored. On the other hand, discharge
in BV is typically whitish or gray with fishy smelling and water
consistency [32,166]. In spite of these differences, AV can be often
falsely diagnosed leading to inappropriate therapy and severe com-
plications particularly in pregnancy [166,167]. Therapy of AV typ-
ically encompasses oral and/or local administration of antibiotics,
antiseptics, estrogens, non-steroidal anti-inflammatory drugs and
probiotics. Among the antibiotics, those active against aerobic bac-
teria, preferably kanamycin, clindamycin and moxifloxacin, are
used, while probiotics are beneficial to increase the lactobacilli
levels. Vaginal atrophy requires hormonal therapy, wherein topi-
cally administered estrogens in combination with antibiotics are
commonly applied [167,168]. If not completely eradicated during
the treatment, AV-associated bacteria can form biofilm (particu-
larly E. coli), similarly as in BV.
4.5.2. Choice of nanoformulation
Most studies on potential local therapy of AV involved liposo-
mal antibiotics (chloramphenicol, azithromycin (AZT), ciprofloxa-
cin), although natural-origin nanomedicines, such as liposomal
resveratrol (RES) were also proposed as well as antiseptics
(chlorhexidine digluconate chitosan/alginate complexes).
A very early research assessing the potential of liposomes in
vaginal therapy was focused on chloramphenicol, broad-
spectrum antibiotic active against AV-bacteria, although at the
time AV has not been defined as specific type of vaginitis. Chloram-
phenicol has been sufficiently encapsulated in both conventional
and elastic propylene glycol liposomes, wherein better entrapment
was achieved with elastic liposomes because of a propylene glycol
solubilizing effect. In vitro liposomes’ stability in the buffers, pH 4.5
and 5.9, indicated greater stability in the pH 5.9 buffer [158], cor-
responding to pH value of the vaginal fluid often found in AV [166].
Better stability of the conventional liposomes was contributed to
the bilayer rigidity reducing leakage of the encapsulated drug13[158]. Conventional liposomes containing chloramphenicol were
incorporated into 1% (w/w) Carbopol 974P gel to assure prolonged
residence within vaginal cavity [63]. The in vitro studies were per-
formed in buffer pH 4.5 in presence of vaginal fluid simulant (VFS,
pH 4.5) [169]. The studies confirmed prolonged and diffusion-
controlled release of chloramphenicol from the liposomal gel.
To treat E. coli-caused AV, Vanić et al. [130] proposed several
types of AZT liposomes, differing in bilayer fluidity and surface
charge. The (phospho)lipid composition, presence of the edge acti-
vator and propylene glycol influenced the encapsulation of AZT,
liposomal size, surface charge, bilayer fluidity, storage stability
and in vitro release under simulated vaginal conditions (VFS, pH
4.5). Optimized AZT liposomes were assessed for ex vivo vaginal
deposition/penetration, in vitro antibacterial activity against several
planktonic and biofilm-forming E. coli strains, as well as in vitro bio-
compatibility with the cervical cells. All liposomesweremore effec-
tive than the free AZT against planktonic E. coli ATCC 700,928 and K-
12 with minimum concentration that inhibited bacterial growth by
50% (MIC50) approximately 3-fold lower than the MIC50 of the free
AZT. Anti-biofilm activity of the AZT liposomes was dependent on
the bacterial strain and type of the liposomes. Variability in the
anti-biofilm activity of different AZT liposomes was a consequence
of the liposomal bilayer properties affectingAZT release and the sus-
ceptibility of thedifferent E. coli strains toAZT. The similar effectwas
confirmed in ex vivo permeability studies. All liposomes enabled
localization of the AZT on/within the vaginal tissue. Hence, the con-
ventional liposomes would be suitable for the treatment of superfi-
cial infections, while DPGs would be appropriate for treating
complicated, biofilm-related, AV infections.
Pisano et al. [75] demonstrated potentials of ciprofloxacin loaded
liquid crystals for topical AV therapy. Liquid crystal structures pro-
vided prolonged release of the encapsulated antibiotic; and were
effective against E. coli with minimum inhibitory concentrations
(MIC) 5-fold lower than those obtained for the free ciprofloxacin.
Since AV is characterized by vaginal inflammation along with
increased levels of aerobic bacteria [32], the utilization of resvera-
trol, exerting both anti-inflammatory and antibacterial properties,
seems to be a very promising strategy, especially when considering
the safe treatment of pregnant women and growing problem of
AMR. Following this approach, Jøraholmen et al. [161] prepared
chitosan-coated liposomes with high RES loading (77%). In addition
to assuring a sustained RES release and retention of nanoformula-
tion at vaginal mucosa, liposomal formulation enhanced in vitro
anti-oxidative and anti-inflammatory properties of RES.
Considering the treatment of non-complicated AV and mixed
vaginal infections, antiseptics such as povidone iodine and
chlorhexidine can also be used [170,171]. Chlorhexidine diglu-
conate was loaded in chitosan/alginate complexes, which were
subsequently freeze-dried to obtain the inserts suitable for vaginal
application. The loaded insert demonstrated strong antibacterial
activity against E. coli. Already after 6 h of the insert incubation
with the bacteria, bacterial concentrations were below the limit
of detection [172].
4.6. Nanomedicine for the treatment of vulvovaginal candidiasis
4.6.1. General considerations
Vulvovaginal candidiasis (also known as vulvovaginal candido-
sis, VVC) is the second most prevalent infection of the lower female
genital tract (after BV) caused by yeast Candida albicans (80–90%),
although other Candida species can be present, such as C. glabrata
(5–10%), C. tropicalis (5%) and C. krusei (1%) [7,52]. Almost 75% of
childbearing age women experience VVC at least once in their life,
while half of them experience recurrent infections [173]. Even
though C. albicans is a part of healthy vaginal microflora, the
imbalance of vaginal microbiota and the progress of the yeasts’
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growth. As a result, the infection process transforms from asymp-
tomatic to symptomatic, comprising virulence factors such as
formation of blastoconidia and pseudohyphae capable of destroy-
ing the vaginal epithelium, as well as the production of enzymes,
toxins and phospholipases [174,175]. Majority of all VVCs are
non-complicated, caused by C. albicans and exhibiting mild symp-
toms. They are often triggered by exogenous factors, such as intake
of antibiotics, and are typically occurring in pregnancy. On the other
hand, complicated (recurrent) VVCs are linked to non-C. albicans
species characterized by four or more recurrent incidents per year.
Recurrent VVCs accompany uncontrolled diabetes mellitus, AIDS,
immunosuppressive or hormone replacement therapy [52,173].
Therapy is commonly relying on oral and/or topical administra-
tion of antifungal agents including pyrimidine analogues, polyenes
and mainly azoles, imidazoles and triazoles. However, the persis-
tent strains (C. parapsilosis, C. krusei, C. glabrata and C. tropicalis),
less susceptible to the antifungal agents, in addition to azoles’
resistance to Candida, contribute to the treatment failures and
recurrence [175,176]. Moreover, Candida is also able to organize
in biofilms, obstructing the sufficient penetration of antifungals
through the formed matrix, thus ensuing increased antimicrobial
resistance and unsuccessful therapy outcome [174,175].
4.6.2. Choice of nanoformulation
Various antifungal-based delivery nanosystems have been pro-
posed for improved VVC topical therapy. Typically, antifungal
drugs used in conventional therapy were encapsulated in different
lipid- and polymer-based nanomedicines (liposomes, solid lipid
NPs, nanostructured lipid complexes, nanoemulsions, polymeric
NPs and nanofibers), alone or incorporated in a secondary vehicle
to improve localization of the drug at the site of infection. Novel
approaches explore the potential of herbal- and seaweed-based
nanomedicines.
Pavelić et al. [158] encapsulated an imidazole derivative, clotri-
mazole, in elastic propylene glycol liposomes and two types of con-
ventional liposomes. Encapsulation of the drug inversely correlated
to the liposomal bilayer fluidity. Inclusion of clotrimazole-
containing liposomes in Carbopol 974 PNF gel positively affected
their stability providing prolonged clotrimazole release [64]. A
favorable balance between the hydrogel’s cohesiveness and adhe-
siveness was achieved, allowing spreading and retention inside
vagina [66]. Ning et al. [177] confirmed the extended release of
clotrimazole from proliposomes. The proliposomes demonstrated
potent antifungal activity without visible changes in the vaginal
tissue.
Jøraholmen et al. [60] studied mucoadhesive, chitosan-coated
clotrimazole liposomes for the VVC treatment in pregnancy. Ex vivo
permeation studies performed on the vaginal tissue of pregnant
sheep, demonstrated reduced clotrimazole permeation from the
coated liposomes in comparison to the non-coated liposomes or
the drug solution. Moreover, concentration of the chitosan used
for the coating of clotrimazole liposomes affected their mucoadhe-
siveness; at the lower chitosan concentrations, mucoadhesiveness
of the liposomes was enhanced.
Chitosan-based nanomedicines offer additional advantages in
the treatment of vaginal infections due to chitosan’s intrinsic
antimicrobial properties and activity in slightly acidic environment
[10,178]. For instance, the activity of empty chitosomes (without
entrapped metronidazole) against C. albicans was comparable to
chitosomes containing metronidazole, wherein metronidazole
itself failed to show any anti-Candida effect [179].
In addition to chitosan, mucoadhesive liposomes can be pre-
pared utilizing other mucoadhesive polymers, such as Eudragit,
Carbopol and pectin. In a very recent study, pectin-coated cationic
liposomes containing sertaconazole nitrate were prepared and14assessed for local VVC therapy. Pectin-coating significantly
reduced zeta potential of the cationic liposomes, increased encap-
sulation and permitted sustained release of the sertaconazole
nitrate. The optimized liposomal formulation, coated with 0.1%
pectin and incorporated into 1% hydroxypropylmethylcellulose
gel showed reduced permeation of the drug into vaginal tissue in
comparison to the control gel. The superiority of the formulation
was confirmed in vivo on C. albicans infected rats, where sertacona-
zole nitrate liposomal gel enabled a significant reduction of micro-
bial count and diminished inflammatory responses with the
minimal histopathological changes of vaginal tissue in comparison
to the control gel [180].
To enhancevaginal delivery of liposomal ciclopirox olamine, Kar-
imunnisa and Atmaram [181] used poly(acrylic)acid-based gel. Vis-
cosity measurements, as well as oscillatory stress sweep and
frequency sweep tests, conducted under dilution of the liposomal
gels with simulated vaginal fluid (VFS), proved pseudoplastic fea-
tures of the formulation. Moreover, extended drug release from
the liposomal gel determined its in vitro antifungal activity; C. albi-
cans was eradicated after 6 h in comparison to 3 h for the free drug
[181].
Contrary to the majority of the findings obtained with the lipo-
somal gels, where sustained release of the encapsulated drugs was
reported [61–66,181]. Kang et al. [182] demonstrated increased
release of amphotericin B from the cationic liposomes incorporated
into thermosensitive gel. The authors proposed that such findings
could be a consequence of the amphiphilic nature of the drug
and its high molecular weight.
In a study by Melo and collaborators [183], negatively surface
charged Eudragit RL100 NPs coated with hyaluronic acid
(<200 nm) allowed controlled and continuous release of ampho-
tericin B in buffer pH 5.5 during 96 h following zero order kinetic
profile. The released therapeutic doses of amphotericin B effi-
ciently inhibited growth of C. albicans in vitro and permitted rapid
and complete yeast elimination in in vivo VVC model (rats). Pres-
ence of hyaluronic acid on the nanoparticles’ surface facilitated
interaction with CD44 receptor in the membrane of vaginal epithe-
lial cells permitting internalization by the cells via receptor-
mediated endocytosis.
Amaral et al. [184] confirmed superior in vivo anti-Candida
activity of miconazole-loaded chitosan nanoparticles (CNPs) in
VVC murine model in comparison to conventional miconazole
cream. However, the amount of the drug used in the chitosan-
based NPs was almost seven-fold lower than in the conventional
cream formulation. Moreover, cytokine production assessed by
monitoring the levels of tumor necrosis factor alpha (TNF-a), and
interleukins 10 (IL-10) and 12 (IL-12) demonstrated significant
decrease for both empty and miconazole-loaded NPs, suggesting
that CPNs-mediated cytokines suppression might be mechanism
responsible for potentiating antifungal activity.
CPNs have also been studied as a carrier for thiosemicarbazide,
a synthetic compound with multiple activities including antifungal
activity. In vivo evaluation in VVC murine model showed similar
efficacy of both free and chitosan-loaded thiosemicarbazide
against C. albicans. However, histopathological evaluation dis-
played the absence or mild inflammation in the group treated with
the thiosemicarbazide NPs, while treatment with the free drug
revealed reduced inflammation in comparison to control [185].
Ravani et al. [186] demonstrated potential of clotrimazole-
loaded nanostructured lipid carriers (NLCs) embedded in ther-
mosensitive hydrogel for the local VVC therapy. Pluronic-based
favorably affected ex vivo localization of the drug in vaginal tissue
with increased in vitro antifungal activity. The authors postulated
that the increased activity was caused by the hydrogel facilitating
intimate contact of the drug-loaded NLCs with C. albicans. The
hydrogel beneficially affected the HeLa cell viability, too.
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topical VVC therapy. SNLs-based Carbopol 940 gel provided sus-
tained release of luliconazole with suitable anti-Candida activity
in vitro. Physicochemical assessment confirmed the stability of
the formulation during two months storage at room conditions
[187].
In study by Nematpour and collaborators [188], anti-Candida
properties of mucoadhesive clotrimazole-loaded nanofibers were
compared to vaginal films. Although both formulations provided
complete release of clotrimazole in 60 min, the nanofiber formula-
tion exhibited greater mucoadhesiveness and stronger anti-fungal
effect as compared to the vaginal film. On the contrary, PLGA nano-
fibers permitted delivery of therapeutic doses of amphotericin B
over 8 days enabling effective in vitro antifungal activity; the single
treatment with fibers eliminated in vivo vaginal fungal burden in
the murine VVC model after 3 days [189].
Application of herbal- and seaweed-based medicines presents
an alternative approach for the treatment of vaginitis as many of
them exhibit multiple favorable activities including antimicrobial,
anti-oxidative and anti-inflammatory. However, the challenge
associated with their application lies in their poor solubility and
bioavailability, which could be overcome by nanotechnology
approach. In a very recent study clove essential oil was entrapped
in nanoemulsion-based emulgel for the possible VVC treatment.
Physico-chemical properties of the nanoemulsion contributed to
its stability during 12 weeks storage. In vitro antifungal studies
revealed lower activity of nanoemulsion compared to the free
clove oil because lower liposolubility of nanoemulsion reflected
to inferior penetration into the lipid membranes of the yeast. How-
ever, superior anti-oxidative activity of the nanoemulsion plays an
important role in suppressing inflammation caused by C. albicans
infection [190].
Arumugam and Rajendran [191] evaluated anti-Candida activ-
ity of callophycin A (seaweed derived metabolite) loaded in both
CNPs and spicules from marine sponges. In vitro studies demon-
strated better loading of callophycin A in CNPs and subsequently
stronger activity against C. albicans than callophycin A-
conjugated spicules, wherein the antifungal efficacy was almost
comparable with 1% clotrimazole cream. In vivo studies performed
on C. albicans animal model showed a significant reduction in the
fugal burden of vaginal lavage by chitosan-based nanoformulation
and protective effect to vaginal mucosa in infected animals.
Pronounced antifungal activity of chitosan has also been con-
firmed in a study by dos Santos et al. [174]. Chitosan hydrogel
embedding nanoemulsion of Peargonium graveolens essential oil
provided strong antifungal activity against Candida spp., with
MIC values almost 64-fold lower than the MICs s for nanoemulsion
of P. graveolens essential oil. Good mucoadhesiveness of chitosan
hydrogel enabled prolonged retention of P. graveolens nanoemul-
sion on the vaginal mucosa and decreased its irritation score.
Interesting approach to treat candidiasis was recently proposed
by Giordani et al. [26]. VVC is known to cause itching, pain and
inflammation at vaginal site. The authors utilized antimicrobial
polyphenols for multitargeted therapy, namely novel liposomes
for simultaneous delivery of two polyphenols (quercetin and gallic
acid) acted in synergy to eradicate infection while alleviating the
symptoms of VVC. Quercetin was selected for its anti-itching and
anti-inflammatory properties, while gallic acid for its anti-
Candida activity. Liposomes bearing both polyphenols consider-
ably reduced C. albicans growth in vitro.
4.7. Nanomedicine for the treatment of viral genital infections
4.7.1. Nanomedicine for the treatment of genital herpes
4.7.1.1. General considerations. Genital herpes is a common sexually
transmitted disease, affecting 491 million persons worldwide15[192]. The infection is caused by herpes simplex virus-2 (HSV-2),
often leading to lifelong infection and periodic reactivations. The
clinical signs of infection encompass single or clustered vesicles
on the perineum, genitalia, upper thighs, buttocks, or perianal
areas that ulcerate before resolving. The subsequent incidences
are affected by reactivation of latent virus; and are usually milder
[193]. The HSV-2 infection increases the risk of infections by HIV-1,
as well as chlamydia and syphilis [193–195]. It is currently consid-
ered to be incurable disease, because of a lack of available vaccine,
as well as the drugs that are fully effective in virus eradication or
prevention of lifelong latency. Namely, HSV-2 effectively escapes
the host immune system, remains latent in neurons, infects new
individuals and cause multiple complications, such as aseptic
meningitis, encephalitis, hepatitis, neonatal infection, pelvic
inflammatory disease and pneumonitis. Neonatal herpes presents
a substantial risk for morbidity and mortality in neonates, thereof
efficient management of the infection in pregnant women is
urgently required [196]. Therapy is commonly comprising oral
nucleoside analogues such as acyclovir, famciclovir or valacyclovir,
the drugs characterized by low bioavailability and numerous side
effects. Moreover, their frequent and long-term clinical use results
in development of drug-resistant strains [193]. Therefore, there is
an urgent need for development of new topical therapeutic plat-
forms enabling efficient antiviral therapy.
4.7.1.2. Choice of nanoformulation. Various nanotechnology strate-
gies have been examined for prevention and eradication of HSV-
2 infections. For instance, zinc oxide tetrapod micro-
nanostructures were designed to prevent attachment of HSV-2 to
the cells and neutralize the virions. When infected with HSV-2 viri-
ons that were pre-incubated with the nanostructures, human vagi-
nal epithelial and cervical HeLa cells, exhibited significantly
reduced infectivity due to ability of tetrapods to bind the HSV-2
virions. Additional increase of the antiviral activity was obtained
following illumination of zinc oxide tetrapods with UV light
[197]. In a study by Halder et al. [198] monodispersed gallic
acid-stabilized gold nanoparticles (7 nm) strongly inhibited HSV-
2 infection by preventing viral attachment and penetration into
the Vero cells. Consequently, the EC50 was 38 mM in comparison
to acyclovir (13 mM), while the cytotoxicity decreased. Following
green synthesis approach, tannic acid, a plant-derived antiviral
compound, was used as a functionalizing ligand in preparation of
silver nanoparticles (AgNPs). Such antiviral nanoformulation
exhibited multi-targeted antiviral mechanism that included block-
ing the viral attachment, preventing its entrance in the cells, and
stimulation of antiviral cytokine and chemokine production. The
HSV-2 infected mice, which were intravaginally treated with tan-
nic acid-modified AgNPs (33 nm), demonstrated better clinical
scores and lower virus titers in the vaginal tissues shortly after
the treatment. Following recurrent infection, the vaginal tissues
treated with the nanoformulation displayed a significant improve-
ment of anti-HSV-2 immune responses by stimulating B cells’ acti-
vation and plasma cells’ homing. It was assumed that the
developed NPs assisted in transfer of HSV antigens to draining
lymph nodes, where naïve B cells can recognize and activate
long-term anti-HSV-2 memory [199].
To enhance poor bioavailability of acyclovir several research
groups suggested its encapsulation in liposomes, polymeric NPs
and microemulsions. Encapsulation of acyclovir in propylene gly-
col liposomes increased its solubility, while the surface charge of
the vesicles affected their stability at simulated vaginal conditions
(VFS with addition of mucin, pH 4.5). The positively charged
(cationic) liposomes were the most stable, probably because of
their interaction with the negatively charged mucin, protecting
the cationic liposomes from unfavorable low pH and vaginal fluid
components. Incorporation of the acyclovir liposomes in the
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mucosa, preserved their original size distribution and additionally
sustained release of acyclovir [65]. Ramyadevi et al. [200] devel-
oped thermosensitive gel incorporating cationic polymeric NPs
that permitted controlled release of therapeutic doses of acyclovir.
The formulation improved drug permeability through vaginal
mucosa and extended its release. In vivo studies in the rat model,
confirmed maintenance of the average therapeutic drug level for
24 h and 2–3-fold better tissue distribution in comparison to that
obtained with the free drug. Significant enhancement in the mean
residence time of the drug was obtained with a 2-fold increase in
the relative bioavailability compared to that of the free acyclovir.
Due to the high ratio of surfactants in their composition,
microemulsions can enhance the drug solubility and subsequently
its bioavailability. In a study by Deshkar et al. [201], acyclovir was
formulated in microemulsion-based thermosensitive gel. The opti-
mized formulation exhibited acidic pH, enabled sustained drug
release during 8 h, and provided shear-thinning behavior with
the gelation temperature in the range 30–35 C.
Neutral mucus-penetrating NPs (MP-NPs), are of particular
importance for advanced drug delivery into the deepest layers of
vaginal mucosa. Ensign et al. [92] demonstrated that MP-NPs pro-
vided uniform distribution over the vaginal epithelium, penetrated
into the deepest mucus layers, and were retained for more than
6 h. Intravaginal application of acyclovir loaded MP-NPs prior
HSV-2 infection protected 53% of mice, while only 16% were pro-
tected in the group treated with acyclovir solution, even at 10-
fold higher drug concentration.
Novel approaches for the management of genital herpes involve
advanced delivery of siRNA molecules and hyper-branched catio-
nic polymers exhibiting antiviral activity. Namely, siRNA mole-
cules can lower the level of proteins encompassed in HSV-2
infection and proliferation, but their use is restricted due to poor
intracellular delivery and short-term activity [202]. To overcome
these limitations, Steinbach et al. [203] developed PLGA NPs incor-
porating siRNA permitting high siRNA loading and controlled
release in vitro. Intravaginal administration of NPs enabled effec-
tive prevention of genital HSV-2 infections in mice, by siRNA-
mediated knockdown of the host cell protein (nectin). The animals
infected with a lethal dose of HSV-2, and cured with siRNA-loaded
PLGA NPs, demonstrated improved survival from more than
28 days (treated animals vs 9 days untreated animals) without
signs of inflammation.
Vaginal administration of branched low molecular weight poly-
ethyleneimine (PEI) has shown prophylactic activity against geni-
tal herpes in mice [204]. When incorporated in liposomes
(<200 nm) and administered at a dose of 0.2 mg PEI and 0.4 mg
lipid/mouse, the increased activity towards HSV-2 infection in
comparison to acyclovir has been obtained, without acute lesions
or toxicity before and after infection. Reduced cellular associations
of PEI liposomes induced higher antiviral effect [205].
Dendrimers have been established as outstanding microbicides.
Precisely, sulphonate-terminated anionic poly(lysine) dendrimer
(SPL 7013), formulated as hydrogel (VivaGelTM), have been clinically
confirmed to be effective in prophylaxis of HIV and HSV-2 infec-
tions [206]. Other dendrimers, such as carbosilane dendrimers,
have also revealed antiviral effect [207]. For instance, Ceña-Diez
and collaborators [208] have assessed in vitro and in vivo anti-
HSV-2 activities of several carbosilane dendrimers in preventing
vaginal and rectal HSV-2 transmissions. G2-S16, G1-S4, and G3-
S16 dendrimers exhibited the strongest activity toward HSV-2
in vitro. They inhibited binding and internalization of HSV-2 into
Vero cells; the activity was most pronounced when the dendrimers
were applied one hour post HSV-2 infection. The superiority of the
carbosilane dendrimers has been proven in vivo; vaginal or rectal
application of G1-S4 or G2-S16 inhibited almost 100% HSV-216transmission in BALB/c mice. The carbosilan-based dendrimers
exhibited in vitro synergistic activity against HSV-2 when applied
together with acyclovir and tenofovir. This was because all tested
antivirals acted at different phases of viral cycle; carbosilane den-
drimers at entry level, acyclovir prevented viral replication, while
tenofovir inhibited HSV-2 DNA polymerase, respectively.
4.7.2. Nanomedicine for treatment of human papilloma virus
4.7.2.1. General considerations. Human papilloma virus (HPV) is a
causative pathogen responsible for a significant proportion of can-
cers and precancerous lesions in both women and men [209]. The
HPV infections are among the most common STIs; approximately
75% of society will acquire this HPV infection at least once in their
lifetime [210]. HPV infection is a highly contagious infection trans-
mitted via mucosal surfaces [211]. The efficient anti-viral therapy
to treat HPV infections remains a challenge [212]. The current
treatment is painful, causing serious systemic and local adverse
effects, while failing to eliminate the latent viral infection [213].
siRNA-based therapy presents a novel approach for the prevention
and treatment of a wide range of diseases, including STIs [214].
However, vaginal siRNA nanomedicine remains, at least up to
now, a rather neglected area in comparison to conventional
approach established on encapsulation of antiviral drugs, but offers
a great potential, especially for the treatment of HPV-caused cervi-
cal cancer [215]. The pioneering research by Wu et al. [216]
demonstrated importance of PEGylated siRNA lipoplexes to allow
sustained and effective delivery of siRNA to female reproductive
tract. Nevertheless, the most success in prophylaxis of HPV infec-
tions has been attained by vaccines based on virus-like particles
(VLP) that gained recognition as efficient preventive measure in
combating cervical cancer [217].
4.7.2.2. Choice of nanoformulation. Although prophylactic vaccines
gained wider acceptance and availability, there are limited options
to treat HPV-associated lesions, while there are no antiviral thera-
pies targeting HPV infections. Foldvari and Moreland [58] intro-
duced nanomedicines in the search for localized treatment of
genital HPV infections. In this preliminary clinical study, liposomal
interferon a (IFN-a) was applied to genital warts caused by HPV in
two patients, however, results were inconclusive. IFN-a is
approved for intralesional injection in treatment of genital warts,
however, it is painful and limited to visible lesions. In a later study,
Foldvari et al. [218] tested the effect of locally applied IFN-a in
patients with genital warts. IFN-a was encapsulated in biphasic
vesicles comprising submicron emulsion and phospholipid-based
vesicles. After 2 weeks treatment, wart size decreased, and resolu-
tion of smaller lesions was confirmed [218].
The use of PEG on nanoparticle surface has shown to enable a
closer contact to mucosal tissue, potentially improving the antivi-
ral effectiveness of drugs administered locally. Jøraholmen et al.
[93] used PEG as coating material to obtain mucus-penetrating
liposomes for improved delivery of IFN-a. The PEGylated lipo-
somes avoided interactions with mucin and improved IFN-a pene-
tration through vaginal tissue.
4.7.3. Nanomedicine for the prevention of HIV infections: Importance
of nanomicrobicides
4.7.3.1. General considerations. Although great efforts are being
made to prevent and combat the spread of a serious COVID-19
pandemic, sexually transmitted HIV infection continues to be a
global challenge having claimed nearly 33 million lives so far
[219]. Following transmission, the virus remains in the mucosal
tissues and spreads to the lymphoid organs, where primarily
infects the CD4 + T cells over envelop glycoprotein gp 120. It causes
a progressive weakening of the immune system until the
patient descent into an immunodeficient state called acquired
Fig. 8. Characteristics of optimal microbicide.
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weekens and diseases develop. The virus transmission occurs also
from mother to child during pregnancy, labor and breastfeeding,
and requires antiretroviral therapy of both HIV-positive mother
and infant [220]. According to theWHO report for 2019, there were
38 million HIV positive people, living with HIV worldwide receiv-
ing lifelong oral antiretroviral therapy [219]. Moreover, growing
drug resistance to HIV, due to the virus ability to mutate and repli-
cate in the presence of antiretroviral drugs, significantly contribute
to the therapy failure, particularly with the first-line drugs, such as
efavirenz [221]. Very high levels of HIV drug resistance, up to 69%,
were seen in infants born by HIV-infected mothers [222]. Unfortu-
nately, to date, all attempts to develop anti-HIV vaccine were17unsuccessful, and condoms and microbicides play a substantial
role in controlling the spread of HIV.
Microbicides are substances designed as vaginal or rectal formu-
lations to prevent or reduce the spread of STIs, especially HIV [223].
They can exhibit differentmechanism of action; by increasing natu-
ral protection mechanism, formation of a physical barrier between
cell and pathogens, blocking viral entrance into the cells, inactivat-
ing cell mechanisms or inhibiting viral replication [224]. Based on
the mechanism of antiviral action, microbicides are classified as:
 HIV-nonspecific compounds, i.e. microbicides without
antiretroviral drugs (acidifiers, surfactants, polyanions, gp120
neutralizing monoclonal antibodies), and
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viral drugs (entry inhibitors, inhibitors of viral replication or
viral enzymes like maraviroc, tenofovir, dapivirine, raltegravir,
sanquinavir, etc.) [223–224].
Microbicides display antiviral activity at the different sites in
genital tract. For instance, viruses can be inactivated in vaginal
environment by surfactants, polyanions, and monoclonal antibod-
ies or at the mucosal level by maintenance the healthy vaginal pH
with acidifiers. On the other hand, entry inhibitors can prevent
internalization into CD4 + T cells when the virus crosses the vagi-
nal epithelial layer (ibalizumab) or via blocking viral replication
with viral enzyme inhibitors such as tenofovir, dapivirine, ralte-
gravir, ritonavir, and sanquinavir [224]. The proposed characteris-
tics of an optimal microbicide are summarized in Fig. 8.
Unfortunately, some of the perspective microbicides including
nonoxynol-9 and SAVVY gel (surfactants) were withdrawn because
they were ineffective in HIV prophylaxis, and contrary to expecta-
tion, enhanced the incidence of genital lesions increasing the risk
for both HIV and other STIs [225–226]. Likewise, polyanion (PRO
2000 gel) and acidifier (BufferGel) exhibited little or no protective
effect in preventing HIV infections although the acidifier was well
tolerated by women [227]. Currently, most of the available micro-
bicides are antiretroviral drugs; however, fully effective and safe
microbicide is still not available [220].
4.7.3.2. Nanomicrobicides (microbicide-loaded nanomedicines). To
overcome the limitations of conventional microbicides by improv-
ing bioavailability and biocompatibility and/or reducing their sys-
temic exposure, research focus in last decades have been on
developing nanomicrobicides. Nanotechnology allows protection
of encapsulated sensitive drugs, modulation of drug release profile,
enhanced intracellular/targeted drug delivery, and improved drug
safety/toxicity issues, finally resulting in increased microbicide
activity [228]. Particularly interesting are nanomedicines exhibit-
ing intrinsic antiviral activity such as dendrimers and inorganic
NPs, as discussed later in this subchapter.
A variety of polymeric NPs, including conventional, mucoadhe-
sive, mucus-penetrating or stimuli responsive NPs, were studied as
carriers for antiviral agents (tenofovir, dapivirine, raltegravir, grif-
fithsin, etc), as well as nanofibers and liposomes. For instance,
Meng et al. [82] prepared mucoadhesive, chitosan-based NPs to
enable controlled release of tenofovir and maximize its contact
with vaginal mucosa. Low encapsulation of tenofovir (6%), a limita-
tion for effective drug delivery, has been significantly increased
(20%) by addition of ethanol as a chitosan co-solvent modified
the release profile and mucoadhesiveness. Continuing the research
with chitosan–thioglycolic acid-conjugated NPs containing teno-
fovir, 5-fold higher mucoadhesiveness was obtained as compared
to CNPs [229].
The ability of nanomedicines to provide stimuli responsive
release is considered beneficial. Since HIV’s transmission occurs
via seminal fluid, which significantly changes the vaginal condi-
tions from acidic to neutral/slightly alkaline [230], neutralization
was used as a trigger in tenofovir and tenofovir disoproxil fumarate
loaded pH-sensitive NPs. PLGA/Eudragit S-100 NPs facilitated
bioresponsive release of encapsulated drug in the presence of
semen fluid simulant (SFS, pH 7.6,) up to 70%, while about 20% of
the drug was released in VFS (pH 4.2). Approximately, 50% of the
drug was internalized by vaginal cells in 24 h by caveolin-
mediated endocytosis. The microbicide-loaded NPs were well tol-
erated in human vaginal and endocervical epithelial cells, and Lac-
tobacillus crispatus [231].
Stimuli responsive release of the encapsulated tenofovir was
also achieved via enzyme-triggered release by hyaluronic acid-
based NPs. Namely, presence of hyaluronidase in human semen18was used as a target allowing triggered release of tenofovir. Almost
90% of the microbicide was released after 24 h in the presence of
enzyme (pH 7.1), in comparison to 39% achieved in the absence
of hyaluronidase, while in vitro cytotoxicity studies demonstrated
biocompatibility with vaginal epithelial cells [232].
Continuing the research with tenofovir, Agrahari et al. [233]
evaluated microbicidal potential of bioresponsive, mucoadhesive
nanofibers. A thiolated hyaluronic acid, used to prepare
tenofovir-loaded electrospun nanofibers, triggered rapid release
of tenofovir within 1 h (87%) in the presence of hyaluronidase.
Such release profile was considered beneficial in comparison to
slow release of tenofovir from hyaluronic NPs [232]. Besides,
in vitro anti-HIV studies proved that tenofovir nanofibers inhibited
the replication of pseudo typed HIV virus and that drug activity
was preserved after the electrospinning process. Following vaginal
administration in mice, improved drug bioavailability in vaginal
tissue was attained without significant CD45 immune cell-
infiltration [233].
Despite of great promises of tenofovir-loaded nanomedicines,
their main obstacle remains limited association of the drug with
both hydrophobic and hydrophilic polymeric nanomedicines
resulting in lower encapsulation efficiency in comparison to other
antiretroviral drugs, such as dapivirine [234]. However, inclusion
of hydrophobic excipients in polymeric NPs, such as stearylamine,
significantly increased loading of tenofovir. To prolong the reten-
tion of the drug at mucosal tissue, the tenofovir-loaded PLGA/
stearylamine NPs were incorporated into mucoadhesive film. The
release of the drug occurred by biphasic pattern with 30% of teno-
fovir released in 30 min followed by slower release (up to 24 h).
Although the cytotoxicity of the formulation was enhanced by
incorporation of stearylamine, it has still remained at the levels
acceptable for vaginal delivery. Following once-daily administra-
tion for 14 days (mice), the formulation confirmed its safety [235].
Dapivirine, a non-nucleoside reverse transcriptase inhibitor, is a
highly potent microbicide that has been clinically investigated in
various dosage forms including gel, ring and film [236]. Very
recently, European Medicines Agency (EMA) approved dapivirine
ring for HIV prevention in women with high HIV burden settings
[237]. Since the drug is characterized by poor water solubility
and low selectivity index [236], research efforts have also been
directed to engineering nanomedicines that could potentiate dapi-
virine anti-viral activity and simultaneously reduce its cytotoxic-
ity. Poloxamer 338 NF (PEO), sodium lauryl sulfate (SLS) and
cetyltrimethylammonium bromide (CTAB) surface-modified poly
(e-caprolactone) (PCL) NPs containing dapivirine were prepared
by nanoprecipitation method allowing nearly 100% association of
dapivirine. All prepared NPs were in the size range 180–200 nm
and permitted favorable fast release of the microbicide within 1–
2 h of incubation in buffer, pH 7.4 and VFS, pH 4.2, followed by
slower release rate [78]. Surface modification of the PCL NPs
affected their stability during storage. Thus, negatively charged
PEO-PCL and SLS-PCL NPs maintained their initial size and dapivir-
ine content up to one-year storage at 5–40 C. On the other hand,
positively charged CTAB-PCLs aggregated in a period of 30–90 days,
depending on the storage conditions. Such instability of the catio-
nic nanoparticles has reflected to in vitro release profile, where
approximately only 40% of dapivirine was released after one-year
storage, while PEO-PCLs and SLS-PCLs release profiles remained
unchanged [238]. Regardless of the surface charge, all NPs
improved cellular uptake of dapivirine by several epithelial and
immune cell lines, used for microbicide assessment. PEO-PCL NPs
revealed enhanced antiviral activity and reduced cytotoxicity.
SLS-PCL NPs demonstrated similar in vitro toxicity profile as free
dapivirine, while CTAB-PCL NPs exhibited high cytotoxicity [78].
Further research on the interaction of the NPs with VFS containing
mucin, demonstrated impact of the surface charge on the transport
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tively charged PEO-PCL and SLS-PCL NPs displayed subdiffusive
transport, while positively charged CTAB-PCL dapivirine NPs inter-
acted with the negatively charged mucin causing their inability to
cross the mucus layer. Changing the pH of VFS from 4.2 to pH 7
reflected to NPs’ diffusivity. Negatively charged NPs needed up to
1.7 h to cross the mucus layer, compared to 7 h required for
CTAB-PCL NPs [239]. Surface modification of NPs also affected their
permeability/retention in the tested cell monolayers (CaSki and
Caco-2 cells) and pig’s vaginal/rectal mucosa. Thus, PEO-PCL NPs
reduced penetration of the drug through the monolayers and
mucosal tissues in comparison to increased permeation attained
with CTAB-PCL NPs, while SLS-PCL NPs did not affect drug perme-
ability. Interestingly, all NPs improved accumulation of the drug in
the mucosal tissues and the cell monolayers as compared to the
free drug [240]. Since PEO-PCL NPs were the most promising dapi-
virine carrier, they were evaluated in vivo in a female mouse to
determine their cervicovaginal distribution, pharmacokinetics
and safety. Although high proportion of the NPs (70%) was rapidly
eliminated due to the liquid nature of the nanoformulation, the
retained NPs were distributed throughout vagina and lower uterus,
crossed the mucus and penetrated the epithelial cells. Moreover,
pharmacokinetic evaluation confirmed localization of dapivirine
in vaginal lavages, vaginal and lower uterine tissues, while the sys-
temic exposure decreased as compared to the free drug. Finally,
during once-daily application for 14 consecutive days, dapivirine-
loaded PEO-PCL NPs were found to be safe [241].
The aforementioned studies clearly indicate that the size and
surface properties have an important role in nanomicrobicides
delivery. Generally, the NPs ranging between 100 and 500 nm
allow deeper penetration into the mucus to reach the epithelial
cells. They should be insensitive to dilution and pH rising upon
ejaculation [47], and finally, be made of biocompatible materials
assuring safe use over longer period.
Following this approach, das Neves et al. [242] evaluated
dapivirine-loaded PLGA NPs. Compared to the previously reported
PCL NPs [78], lower dapivirine encapsulation was obtained in
170 nm-sized PLGA NPs (up to 80%) because of the lesser
hydrophobicity of PLGA, restricting complete association of the
drug with the polymer. Subsequently burst dapivirine release
occurred in 4 h [242] in comparison to the release from PCL NPs
in 1–2 h [78]. Presence of mucin significantly reduced the transport
of dapivirine across HEC-1-A and CaSki cell monolayers both as
NPs and free dapivirine, but the drug retention in the monolayers
was enhanced for NPs [242].
In addition to single drug encapsulation, nanoformulations
allow loading of two or more microbicidal compounds in the same
nanoformulation. For instance, Yang et al. [243] designed PLGA NPs
containing two antiretroviral agents, griffithsin and dapivirine,
with the aim of providing sufficient and long-term HIV prophylaxis
via targeting the fusion with CD4 + T cells (griffithsin) and tran-
scription phase of HIV replication (dapivirine). Both microbicides
were efficiently encapsulated in PLGA NPs (180–200 nm), either
individually or simultaneously (40–45% griffithsin, 70% dapivirine),
and were biocompatible with the in vitro model of cervical cells
maintaining anti-HIV activity. The application of the microbicides
at ratio 1:1 of IC50 values resulted in strong synergistic activity
for both free and PLGA-loaded microbicides. Opposite to the find-
ings by das Neves’ group, where dapivirine was released in a few
hours, Yang et al. [243] demonstrated slow release of both micro-
bicides over 7 days (in buffers pH 7.4 and 4.5), suggesting reduced
dosing frequency to a weekly-based regimen. However, no studies
have been performed in the presence of the simulated mucus layer,
known to significantly affect the delivery of both free drug and
NPs-based drug.19Co-administration of several antiretroviral drugs offers virus
targeting via different mechanism of action. Moreover, nanomicro-
bicides offer reduction of the required dose, improved localized
effect, safety and possibly, reduced dosage frequency.
In a very recent study, Minooei et al. [244] evaluated synergistic
activity of oxidation-resistant variant of griffithsin (Q-GRFT) with
several antiretroviral drugs (tenofovir, raltegravir and dapivirine),
differing from each other in solubility and mechanism of antiviral
activity. Each of the drug was sufficiently encapsulated in PLGA
NPs (ranging from 15% for tenofovir up to 100% for raltegravir),
which facilitated slow release of the individual drugs in VFS (pH
4.5) during 14 days. All drug-loaded NPs were well tolerated by
VK2, Ect1 and Ed1/E6E7l cells up to 72 h, with exception of dapivir-
ine NPs (48 h), probably due to the faster release of the drug con-
tributing its cytotoxicity. Co-administration of free Q-GRFT with
each free antiretroviral drug led to strong synergistic interactions,
relative to each agent alone. Moreover, when the different drug-
loaded PLGA NPs were co-administered with the Q-GRFT-loaded
NPs, synergy across all nanoformulations was achieved, with the
most potent interactions between nanoparticle-loaded Q-GRFT
and dapivirine. Embedding of the Q-GRFT-loaded NPs and
dapivirine-loaded NPs in PEO-PCL-multilayered nanofibers
resulted in burst release of dapivirine that can provide rapid HIV
protection, followed by more sustained release of Q-GRFT for
long-term prophylaxis and treatment.
There are several other studies exploring potential use of
nanomicrobicides based on the combination of antiviral agents
(Table 1).
Cunha-Reis and collaborators [245] prepared tenofovir- and
efavirenz-loaded PLGA NPs embedded into fast dissolving film
facilitating prolonged retention of the nanomicrobicides at vaginal
lavages and tissue in vivo. Although local concentrations for both
drugs rapidly declined during time, association between the NPs
and film improved the pharmacokinetic profile of efavirenz espe-
cially in the first 2 h after formulation administration. In another
study, co-administration of efavirenz with raltegravir via PLGA
NPs resulted in lower 90% effective concentration (EC90) values
than solution of both drugs; however, the difference between the
drugs-in-NPs and solution was not significant. The NPs were not
cytotoxic to HeLa cells during 14 days, and the intracellular con-
centrations of efavirenz were above EC90 for 14 days, while ralte-
gravir intracellular concentrations were eliminated in 6 days.
Incorporation into thermosensitive gel facilitated retention of the
NPs at the cervicovaginal tissue, permitting transport of the NPs
in the HeLa cells [81].
Contrary to all above reported studies on the drug-loaded con-
ventional NPs embedded in a mucoadhesive vehicle, Krogstad et al.
[246] designed mucus-penetrating NPs incorporated in mucoadhe-
sive nanofibers. Such complex mucus-penetrating/mucoadhesive
delivery system enabled enhanced retention of the nanomicrobi-
cide in the genital tract by nanofibers and the fast diffusion of
the efavirenz-loaded PEGylated PLGA NPs through the mucus
layer. The nanofibers have significantly enhanced retention of the
drug-loaded NPs in vivo to at least 3 days. In addition, pharmacoki-
netic showed extremely high efavirenz concentrations in cervicov-
aginal lavage (7 days) and 2-fold higher drug concentrations in
vaginal tissue in comparison to suspension of the NPs, while sys-
temic exposure to efavirenz was very low.
Development of siRNA-based vaginal microbicides presents a
perspective approach for the HIV prophylaxis. To achieve improved
delivery of siRNA across the cervicovaginal mucus, Gu et al. [247]
engineered mucus-penetrating PLGA-PEG NPs and polyethylen-
imine (PEI)/siRNA complexes, functionalized with anti-HLA-DR
antibody (siRNA-NP-Ab). The NPs were embedded in intravaginal
film to allow retention at the cervicovaginal mucosa. Importantly,
Table 1







Active ingredient(s) Outcome Reference
HIV Polymeric nanoparticles Film Tenofovir Retention of the nanoparticles at vaginal mucosa; suitable release
profile for HIV prophylaxis; confirmed safety (in vivo).
Machado et al., 2016 [235]
Tenofovir,
efavirenz
Enhanced retention of the nanomicrobicides in vaginal lavages and
tissue in vivo; improved pharmacokinetic for efavirenz.





Rapid initial release of Q-GRFT and dapivirine, followed by slow release
of Q-GRFT; retention of the microbicides in vaginal cavity; reduced
cytotoxicity in vitro.




Improved retention and localization of the nanoparticles at
cervicovaginal tissue; sustained release and intracellular delivery of
the drugs.





Etavirine Significantly prolonged retention time for nanomicrobicide in vivo (at
least 3 days); rapid transport of the nanoparticles over mucosa; long-
lasting antiviral effect (up to 7 days).




Film siRNA Rapid release of the siRNA-loaded nanoparticles, diffusion through the
epithelial layer and uptake by KG-1-cells; improved targeting activity
and significantly increased knockdown of SNAP-23 mRNA and protein
compared with the nanoparticles without antibody conjugation.




























Active ingredient(s) Outcome Reference
Silver
nanoparticles
Gel (mucoadhesive) - Retention of the nanoparticles at cervicovaginal mucosa; rapid onset of
anti-HIV activity; confirmed in vitro biocompatibility.
Lara et al., 2010 [261]
Liposomes MC-1220 Improved retention of the microbicide at cevicovaginal tissue;
incomplete HIV prophylaxis; confirmed safety (in vivo).




Suitable retention and release of the microbicides at vaginal mucosa;
enhanced permeation of the microbicides and reduced cytotoxicity
in vitro.
Faria et al., 2019 [251]
G2-S16
Dendrimer
- Superior anti-HIV activity in the presence of semen; confirmed
biocompatibility (mouse model).




Gel (mucoadhesive) - Suitable vaginal retention and release of the dendrimers; strong
antiviral activity; safety in several animal models; passed Phase 1
(HIV) and Phase 2 (HSV-2) clinical trials; unsafe for continuous use in
women (rejected).
Rupp et al., 2007 [253]; Notario-Pérez




Gel (thermosensitive) Acyclovir Increased retention and tissue distribution; improved local drug
bioavailability (in vivo).
Ramyadevi et al., 2016 [200]
Liposomes Gel (mucoadhesive) Acyclovir Sustained drug release, affected by the surface properties of the
liposomes; increased in vitro stability and vaginal retention.
Pavelić et al., 2005 [65]
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22siRNA-NPs were rapidly released from the film and able to pene-
trate the epithelial layer to be taken up by differentiated KG-1 cells.
The formulation facilitated significant knock-down of SNAP-23
gene/protein expression by active targeting strategy, without sig-
nificant impact on the cell viability.
Liposomes were also examined as carriers for HIV prophylaxis.
However, there are only a few studies reporting on liposomes as
nanomicrobicides. In one of the first studies, hydrophobic MC-
1220 was encapsulated in conventional liposomes and incorpo-
rated in mucoadhesive gel; MC-1220 was better absorbed, and well
tolerated in the rabbit model [248]. Assessment of the anti-HIV
efficacy in rhesus macaques, confirmed partial protection (50–
60%) against HIV with lower and medium MC-1220 concentrations
in liposomal gels, while the formulation with the highest microbi-
cide concentration failed to enhance the protection level, possibly
due to the low microbicide solubility affected by pH [249].
In a study by Malavia et al. [250] a challenging approach based
on the incorporation of synthetic lipids in liposomes, such as cardi-
olipin, demonstrated that by the balancing of synthetic and natural
lipids enhanced anti-HIV activity can be obtained.
Strategy of vaginal co-delivery of two microbicides in one for-
mulation, reported for polymeric NPs, was also applied for liposo-
mal microbicides. Thus, tenofovir disoproxil fumarate-loaded
liposomes were incorporated into Carbomer gel embedding
emtricitabine. [251]. Such complex formulation enabled sustained
drug release profile with 60% of both drugs released within 3–6 h,
where the fast initial release was obtained with emtricitabine,
while tenofovir disopoxil fumarate release was slower. The drug-
loaded liposomes were non-cytotoxic to HEC-1-A and CaSki cells
and able to facilitate the drug permeation in vitro.
Alukda et al. [252] proposed utilizing polylysine–heparin func-
tionalized SLNs with tenofovir as HIV nanomicrobicide. Despite of
the low encapsulation of tenofovir in functionalized SLNs, the
nanoformulation was able to enhance the cellular uptake of
tenofovir.
Although many of the nanomicrobicides reported above, partic-
ularly polymeric NPs, have shown a promise in preventing HIV
infections, none of them have yet reached the clinical trial. The
only exceptions are dendrimers, more precisely SPL7013 den-
drimer (16,581 Da; Starpharma Pty Ltd, Melbourne, Australia),
which was built from a divalent core, the bezhyldrylamine amide
of L-lysine [83]. SPL7013 was confirmed very effective in prophy-
laxis of both HIV and HSV infections [253], and very lately, against
severe SARS-CoV-2 virus in a form of a nasal spray [254]. The
mechanism of its intrinsic antiviral activity lies in the polyanionic
surface enabling attachment of SPL7013 to gp 120 proteins, thus
obstructing viral fitting to CD4 receptors of the human cells.
SPL7013 was formulated at a concentration of 3% (w/w) in Car-
bopol gel (VivaGelTM) to facilitate the dendrimers retention at cervi-
covaginal mucus. However, despite the great success in preclinical
animal and clinical studies, summarized by Rupp et al. [253]; the
adverse effects associated with the formulation led to its with-
drawal from further clinical investigations [224,255,256].
The inherent antiviral properties of dendrimers are particularly
valuable in terms of the emergence of resistance to conventional
antiretroviral therapy. Among alternative dendrimer-based
nanomicrobicides are polyanionic carbosilane G1-S4 or G2-S16
dendrimers, acting as entry inhibitors similarly as SPL7013. More-
over, G2-S16 exhibited a dual action, namely the inhibition is made
on viral attachment, protecting the cell against viral infection and
acting directly against the virus. In that sense, polyanionic carbosi-
lane dendrimers, G1-S4 and G2-S16, have demonstrated the best
results against HIV-1 infections [257]. However, investigation on
the possible HIV resistance, demonstrated that G1-S4 treatment
caused significant mutations in HIV-1NL4.3. On the contrary, G2-
S16 did not result with resistance-associated mutation, proposing
Table 2
Advantages and limitations of nanomedicines for vaginal drug delivery.
Advantages Limitations
Ability to incorporate a variety of
drugs/active compounds differing in
Mw and lipophilicity
Protection of sensitive drug from
vaginal environment




Ability to deliver high drug load at
the site of action
Potential for active drug targeting
Enhanced intracellular delivery
Reduction of drug dose required for
an efficient therapeutic outcome
Increased antimicrobial activity
(reduced MIC values)
Decreased ability of resistance
development
Compatibility and efficient mobility






Lower loading of hydrophilic drugs
Storage stability
Possible leakage of loaded drug
Limited loading capacity for high
dosing drugs
Long-term safety for human use





MIC, minimum inhibitory concentration.
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S16 dendrimer did not cause any irritation or inflammation in the
vaginal epithelium, proving that this dendrimer is a safe vaginal
nanomicrobicide [259].
Inorganic NPs have also shown promising microbicidal poten-
tial. For instance, PEGylated gold NPs inhibited the viral entry by
binding with gp120 thus preventing CD4 attachment. Interestingly,
their activity was even higher than activity of UC-781 (antiretrovi-
ral drug) in the fusion assay [260]. Similarly, polyvinylpyrrolidone
coated AgNPs exerted anti-HIV activity by the same mechanism of
action as the gold nanoparticles. When incorporated into hydrogel
they enabled effective prevention of the HIV transmission. More-
over, the NPs were not cytotoxic to the explant for 48 h, and impor-
tantly; only 1 min of the NPs pretreatment was required to prevent
HIV-1 transmission. This effect was lasting for 2 days, offering safe
and long-lasting protection of the cervical tissue from infection
[261].
We tried to provide an overview of numerous potentials nano-
medicine offers for the prevention and efficient topical treatment
of the vaginal, as well as genital infections. However, the challeng-
ing limitations slowing nanomedicine’s path to translation, sum-
marized in Table 2 require focused attention. It is expected that
better understanding of the interplay between nanoformulation
and targeted site for drug/active ingredient action might help in
design of optimal nanoformulation.5. Addressing toxicity
With the increased attention on marketed nanoformulations
destined for various administration sites, the issue of potential tox-
icity, especially related to repeated administration, become more
relevant [262]. As a mucosal site, vagina can be potentially affected
by the applied formulations. Considering the localized treatment of
vaginal infections, relying on the administration of antimicrobial
drugs and active ingredients, it is very important to consider the
restoration of normal vaginal microflora, pH, as well as avoidance
of any tissue toxicity. Available literature mostly reports concerns
related to nanocarriers as drug delivery systems for parenteral,23pulmonary and rather recently, skin routes. Toxicity of nanoformu-
lations repeatedly applied to vaginal site deserves more attention
than currently given. Although many of the nanocarriers discussed
in the review have rather impressive safety profile, it is important
to address the potential safety issues, especially for formulations
that are at preclinical developmental stages. The toxicity issues
can range from rather mild concerns such as the buffer strength
of nanoformulation to be applied vaginally that needs to be care-
fully addressed according to the WHO Note on osmolality. The
pH deviations from the normal vaginal pH (acidic) are considered
toxic. More data are available on the safety of vaginal semi-solid
and solid formulations rather than nanoformulations [6,263], prob-
ably since most nanoformulations, with the exception of den-
drimers, have not reached the market. More comprehensive
systemic studies are needed, extending beyond classical cytotoxic-
ity testing [6,263].
Another highly relevant issue is the concentration of nanosys-
tems at the vaginal site. Smaller volumes of nanocarriers exposed
to the cervicovaginal mucus can be safely eliminated by the natural
self-cleansing mechanisms of the genital tract relying on the
mucus turnover and discharge. A higher concentration of NPs
might interfere with the organized mucus causing a collapse of
mucin fibers [47]. Moreover, possible genital irritation and sys-
temic toxicity related to the delivery system especially in biofilm
treatment should be followed [8]. Although dendrimers are one
of the most successful nanoformulation destined for vaginal site,
there are concerns regarding the disruptive effect of charged
dendrimers toward bio-membranes, leading to the cytotoxicity
caused by the aggregation processes involved into cellular mem-
branes [264].
Finally, serious issues such as potential immune response, need
to be urgently considered; it is know that upon the exposure to
vaginal products (even the conventional ones), the vaginal epithe-
lium may respond by secreting immune mediators further enhanc-
ing the susceptibility to STIs. Most of the studies determining the
potential toxicity so far relied heavily on the cell toxicity testing;
even when animal studies were performed, the results are often
rather difficult to directly correlate to human data [265,266]. The
limited choice of reliable models able to predict the safety of
nanopharmaceuticals in a robust manner remains to be considered
a major drawback in the development of microbicides for HIV pre-
vention [267].
Highly relevant for localized therapy of vaginal infections is
assurance that antimicrobials applied locally do not penetrate into
systemic circulation. Chen and Yang [268] demonstrated that the
vaginal administration of nanosilver particles lead to absorption
into blood circulation; vaginal administration caused ultrastruc-
tural changes to the vaginal mucosa, urethra and rectum, with
accumulation of particles in all tissues as evidenced by ultrastruc-
tural pathological changes promoting cytoxicity. The TEM exami-
nation of the hepatic portal vein blood revealed evidences of
migration for the first time. The findings are highly relevant for
localized antimicrobial therapy of pregnant patients where
unwanted systemic exposure could lead to toxicity both to mother
as well as fetal toxicity. Moreover, systemic exposure would be
contraindicated in topical therapy.
6. Conclusions and perspectives
The importance of treating vaginal infections more successfully
brought novel approaches, challenged certain dogmas, as well as
raised public awareness, although still not to satisfactory level.
Comparing to other fields, localized treatment of vaginal infections
is still explored to a limited depth. The urgency to respond to the
increasing treat of AMR summarized in Fig. 9, highlights the need
for novel therapy approaches.
Fig. 9. Vaginal infections in the era of antimicrobial resistance.
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gin of their building blocks, size, surface modifications and their
interaction with the vaginal mucosa. It is rather challenging to
summarize their features as we tried in Table 2, or even more to
propose the superior nanocarrier for localized therapy of vaginal
infections.
We would rather suggest that a deeper insight on the interplay
between:
 Nanoparticle size
 Surface modification (mucoadhesiveness/penetration)
 Load of drug/active ingredient, alone or in combination
 Release profile of the drug/s
 Interaction/synergy with secondary vehicle used to improve
system’s retention at vaginal site
 Safety profile,
needs to be consider when tuning the properties of
nanoformulation.
However, the optimization should also address the particular
challenges the particular infection bears; some of the infections
would require deeper penetration in the epithelial layer, while
for others rather superficial contact between nanocarrier and
microorganism will be sufficient.
From pharmaceutical perspective, the manufacturing of the
nanoformulation, such as simplicity, cost and attractiveness, needs
to be considered.
To optimize the formulation, there is a need for better models
able to predict both qualitative and quantitative profiles of drugs24delivered to vaginal site; animal infection models are very limited;
mechanisms of action of some of the promising active molecules
are not fully elucidated, therefore, in parallel to efforts invested
in optimizing the novel nanoformulation, the development of bet-
ter, more specific and robust in silico, in vitro and animal models is
urgently needed.
In the era of AMR, and emerging threats of STIs resistance to
current first lines of treatment, it is last moment to start seriously
discussing the alternative ways to treat STIs (Fig. 9). There are dif-
ferent pathways which could potentially offer the ‘‘way out” of
raising limitation of available antibiotics:
i) Choice of antimicrobial: novel chemical entities, natural ori-
gin, biomimetics, siRNA-based, ‘‘recycling” of antimicrobials
currently not administered vaginally
ii) Choice of nanoformulations: more focus on synergy between
drug and pharmaceutical ingredients with intrinsic antimi-
crobial properties
iii) Addressing treatment of pregnant patients
iv) Focus on user-friendliness of formulation, often neglected
when designing and optimizing the formulations for vaginal
site. This would enhance the patient compliance.
Finally, addressing the road map to translation, why are there
no more products in clinical trials, reaching the market? What
should be done? The barriers to translation are multiple and rather
hard to address. They range from limited understanding of the
infection targets, not yet smart enough approaches in designing
the targeted delivery systems able to bring the molecules to patho-
gen in an optimal mode, availability of in vitro, in vivo models to
optimize formulation, better correlation between limited animal
and human models, more specific toxicity studies, especially
regarding pregnant patients. However, the societal challenges such
as awareness of increasing prevalence of STIs both in developing
and developed countries need to be address. Finally, addressing a
rather limited focus of health care providers regarding woman
health as well as seeking more attention from pharmaceutical
companies, are the barriers we need to focus on in parallel to sci-
entific efforts.
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